PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18600064-6 2008 The synergistic effect of PGA1 was inhibited by GW9662, a specific peroxisome proliferator-activated receptor (PPAR) antagonist, and Bay-11-7082, a NF-kappaB inhibitor. 2-chloro-5-nitrobenzanilide 48-54 peroxisome proliferator activated receptor gamma Mus musculus 111-115 18028370-5 2008 Treatment of J774.2 cells with the PPARgamma inhibitor GW9662 did not alter tolerance induction because these cells were still hyporesponsive to the secondary LPS challenge. 2-chloro-5-nitrobenzanilide 55-61 peroxisome proliferator activated receptor gamma Mus musculus 35-44 17848638-6 2007 Rosiglitazone-mediated induction of ATGL mRNA and protein is inhibited by the PPARgamma-specific antagonist GW-9662 and is also significantly reduced following siRNA-mediated knockdown of PPARgamma, supporting the direct transcriptional regulation of ATGL by PPARgamma. 2-chloro-5-nitrobenzanilide 108-115 peroxisome proliferator activated receptor gamma Mus musculus 78-87 18343627-3 2008 The protection afforded by FMOC-L-leucine was alleviated by the PPARgamma antagonist GW9662 (1-2 mg/kg) and was induced in 50% animals by 4.8+/-1.2 mg/kg. 2-chloro-5-nitrobenzanilide 85-91 peroxisome proliferator activated receptor gamma Mus musculus 64-73 18261208-21 2008 BADGE did not reverse RGZ effect while the antagonist GW9662 completely abrogated it, suggesting a PPARgamma- dependent mechanism. 2-chloro-5-nitrobenzanilide 54-60 peroxisome proliferator activated receptor gamma Mus musculus 99-108 18354219-7 2008 These effects on C. albicans GI infection and on macrophage activation are suppressed by treatment of mice with GW9662, a selective PPARgamma antagonist, and are reduced in PPARgamma(+/-) mice. 2-chloro-5-nitrobenzanilide 112-118 peroxisome proliferator activated receptor gamma Mus musculus 132-141 17019405-8 2007 In addition, the magnitude of expression of behavioral sensitization was augmented by treatments with GW9662 (a PPARgamma antagonist; 0.5-5.0 microg i.c.v., once daily) during the withdrawal period. 2-chloro-5-nitrobenzanilide 102-108 peroxisome proliferator activated receptor gamma Mus musculus 112-121 17510607-7 2007 The mechanism of inhibition is dependent on PPARgamma because concomitant treatment of animals with the PPARgamma antagonist GW9662 reversed the inhibitory effect of 15d-PGJ2. 2-chloro-5-nitrobenzanilide 125-131 peroxisome proliferator activated receptor gamma Mus musculus 44-53 17510607-7 2007 The mechanism of inhibition is dependent on PPARgamma because concomitant treatment of animals with the PPARgamma antagonist GW9662 reversed the inhibitory effect of 15d-PGJ2. 2-chloro-5-nitrobenzanilide 125-131 peroxisome proliferator activated receptor gamma Mus musculus 104-113 17697525-4 2007 Telmisartan, an Ang II type 1 receptor blocker, downregulated RAGE mRNA and inhibited superoxide generation and MCP-1 gene expression in mesangial cells; these processes were blocked by GW9662, a PPAR-gamma inhibitor. 2-chloro-5-nitrobenzanilide 186-192 peroxisome proliferator activated receptor gamma Mus musculus 196-206 17659579-5 2007 To induce sepsis, the mice were injected with lipopolysaccharide (LPS) and D-galactosamine (GalN) in the presence and absence of the peroxisome proliferator-activated receptor gamma (PPARgamma) inhibitor GW9662. 2-chloro-5-nitrobenzanilide 204-210 peroxisome proliferator activated receptor gamma Mus musculus 183-192 17659579-12 2007 The inhibition of PPARgamma with GW9662 abrogated the protection induced by probiotics. 2-chloro-5-nitrobenzanilide 33-39 peroxisome proliferator activated receptor gamma Mus musculus 18-27 17363128-6 2007 Troglitazone-induced cell death was prevented by the PPARgamma antagonist GW9662. 2-chloro-5-nitrobenzanilide 74-80 peroxisome proliferator activated receptor gamma Mus musculus 53-62 16981222-7 2007 Addition of different specific inhibitors of PPARgamma (GW9662), LXRalpha (GGPP), ABCA1 (DIDS) to the foam cells significantly suppressed LPC-induced cholesterol efflux. 2-chloro-5-nitrobenzanilide 56-62 peroxisome proliferator activated receptor gamma Mus musculus 45-54 15517883-3 2004 Proliferation of DS19 mouse erythroleukemia cells was inhibited by PPAR gamma agonists (4-phenylbutyrate, rosiglitazone, ciglitazone and GW1929) and by potential PPAR gamma antagonists: BADGE (Biphenol A diglycidyl ether), GW9662, PD068235 and diclofenac. 2-chloro-5-nitrobenzanilide 223-229 peroxisome proliferator activated receptor gamma Mus musculus 162-172 16696951-3 2006 The aim of this study is to examine the effects of a synthetic PPARgamma antagonist (GW9662) on adiposity and glycemic control in high-fat (HF) diet-fed mice. 2-chloro-5-nitrobenzanilide 85-91 peroxisome proliferator activated receptor gamma Mus musculus 63-72 15670761-6 2005 GW9662, an antagonist of PPAR-gamma, reduced the effects of ciglitazone and pioglitazone. 2-chloro-5-nitrobenzanilide 0-6 peroxisome proliferator activated receptor gamma Mus musculus 25-35 15809511-13 2005 The PPARgamma antagonist GW 9662 (10(-6) and 10(-5)M) was also ineffective. 2-chloro-5-nitrobenzanilide 25-32 peroxisome proliferator activated receptor gamma Mus musculus 4-13 16091010-5 2005 In contrast, Cx43 induction by astaxanthin but not by a RAR-specific retinoid was inhibited by GW9662, an antagonist of peroxisome proliferator activated receptor-gamma activation. 2-chloro-5-nitrobenzanilide 95-101 peroxisome proliferator activated receptor gamma Mus musculus 120-168 16778009-7 2006 This effect was reversed by guggulsterone, an FXR antagonist, and partially reverted by GW9662 (2-chloro-5-nitro-N-phenylbenzamide), a selective PPARgamma antagonist, indicating that FXR modulates adipocyte-related genes by PPARgamma-dependent and -independent pathways. 2-chloro-5-nitrobenzanilide 88-94 peroxisome proliferator activated receptor gamma Mus musculus 145-154 16778009-7 2006 This effect was reversed by guggulsterone, an FXR antagonist, and partially reverted by GW9662 (2-chloro-5-nitro-N-phenylbenzamide), a selective PPARgamma antagonist, indicating that FXR modulates adipocyte-related genes by PPARgamma-dependent and -independent pathways. 2-chloro-5-nitrobenzanilide 88-94 peroxisome proliferator activated receptor gamma Mus musculus 224-233 16778009-7 2006 This effect was reversed by guggulsterone, an FXR antagonist, and partially reverted by GW9662 (2-chloro-5-nitro-N-phenylbenzamide), a selective PPARgamma antagonist, indicating that FXR modulates adipocyte-related genes by PPARgamma-dependent and -independent pathways. 2-chloro-5-nitrobenzanilide 96-130 peroxisome proliferator activated receptor gamma Mus musculus 145-154 16778009-7 2006 This effect was reversed by guggulsterone, an FXR antagonist, and partially reverted by GW9662 (2-chloro-5-nitro-N-phenylbenzamide), a selective PPARgamma antagonist, indicating that FXR modulates adipocyte-related genes by PPARgamma-dependent and -independent pathways. 2-chloro-5-nitrobenzanilide 96-130 peroxisome proliferator activated receptor gamma Mus musculus 224-233 15993011-6 2005 Co-treatment with the peroxisome proliferator-activated receptor (PPAR)gamma antagonist GW9662 did not inhibit the effect of TBT, suggesting that the observed effect of TBT may not be PPARgamma-dependent. 2-chloro-5-nitrobenzanilide 88-94 peroxisome proliferator activated receptor gamma Mus musculus 66-76 15949684-5 2005 In contrast, Cx43 induction by astaxanthin, but not by a RAR-specific retinoid, was inhibited by GW9662, a PPAR-gamma antagonist. 2-chloro-5-nitrobenzanilide 97-103 peroxisome proliferator activated receptor gamma Mus musculus 107-117 14742672-6 2004 Our findings with the PPAR-gamma antagonist 2-[4-[2-[3-(2,4-difluorophenyl)-1-heptylureido]ethyl]rsqb]-phenylsulfanyl]-2-methylpropionic acid (GW9662) and mouse embryonic fibroblasts lacking PPAR-gamma demonstrate that CDDO and 15-dPGJ2 use PPAR-gamma-independent mechanisms to inhibit collagenase gene expression. 2-chloro-5-nitrobenzanilide 143-149 peroxisome proliferator activated receptor gamma Mus musculus 22-32 14668325-6 2004 The selective PPARgamma antagonist, GW9662, blocked both the positive and negative effects on MPO expression. 2-chloro-5-nitrobenzanilide 36-42 peroxisome proliferator activated receptor gamma Mus musculus 14-23 14758164-15 2004 GW 9662 (1 mg/kg administered intraperitoneally 30 mins before treatment with rosiglitazone) significantly antagonized the effect of the PPAR-gamma agonist and thus abolished the protective effect. 2-chloro-5-nitrobenzanilide 0-7 peroxisome proliferator activated receptor gamma Mus musculus 137-147 15187132-6 2004 Unexpectedly, GW9662, a PPARgamma antagonist, increases lymphocyte IFN-gamma expression. 2-chloro-5-nitrobenzanilide 14-20 peroxisome proliferator activated receptor gamma Mus musculus 24-33 15137925-8 2004 GW9662, a PPARgamma antagonist, reversed the inhibitory effect of rosiglitazone, but not that of PUFA. 2-chloro-5-nitrobenzanilide 0-6 peroxisome proliferator activated receptor gamma Mus musculus 10-19 33380244-8 2021 Furthermore, these effects of 4-HPR in vivo and in vitro including anti-inflammation and modulation of macrophage polarization were partially abolished by treatment with PPAR-gamma antagonist GW9662, indicating that 4-HPR activated PPAR-gamma to exert its activities. 2-chloro-5-nitrobenzanilide 192-198 peroxisome proliferator activated receptor gamma Mus musculus 170-180 14695339-8 2004 The specificity of the phenomenon was confirmed by treating OVA-pulsed DCs with ciglitazone, another PPAR-gamma agonist, and by using GW9662, a PPAR-gamma antagonist. 2-chloro-5-nitrobenzanilide 134-140 peroxisome proliferator activated receptor gamma Mus musculus 144-154 11226258-4 2001 Interestingly, this inhibitory effect can be mimicked by both natural as well as synthetic peroxisome proliferator-activated receptor gamma1 (PPARgamma1) ligands and can be blocked by the irreversible PPARgamma antagonist GW 9662. 2-chloro-5-nitrobenzanilide 222-229 peroxisome proliferator activated receptor gamma Mus musculus 142-151 12855660-5 2003 Although CDDO and CDDO-Im both bind and transactivate peroxisome proliferator-activated receptor (PPAR) gamma, the irreversible PPARgamma antagonist GW9662 does not block the ability of either CDDO or CDDO-Im to induce differentiation; moreover, PPARgamma-null fibroblasts are still sensitive to the growth-suppressive effects of CDDO. 2-chloro-5-nitrobenzanilide 149-155 peroxisome proliferator activated receptor gamma Mus musculus 128-137 33588632-7 2021 Further studies indicated that PPARgamma inhibitor GW9662 activated NF-kappaB pathway after TEC treatment in OGD/R-induced HT-22 cells. 2-chloro-5-nitrobenzanilide 51-57 peroxisome proliferator activated receptor gamma Mus musculus 31-40 33588632-8 2021 Also, PI3K/AKT inhibitor LY294002, PPARgamma inhibitor GW9662 and NF-kappaB activator LPS both reversed the effects of TEC on OGD/R-induced HT-22 cell biology. 2-chloro-5-nitrobenzanilide 55-61 peroxisome proliferator activated receptor gamma Mus musculus 35-44 33380244-8 2021 Furthermore, these effects of 4-HPR in vivo and in vitro including anti-inflammation and modulation of macrophage polarization were partially abolished by treatment with PPAR-gamma antagonist GW9662, indicating that 4-HPR activated PPAR-gamma to exert its activities. 2-chloro-5-nitrobenzanilide 192-198 peroxisome proliferator activated receptor gamma Mus musculus 232-242 34153405-10 2021 PPARgamma antagonist GW9662 and PPARgamma-targeted siRNA were used to investigate the mechanism of icaritin in inhibiting myofibroblast differentiation. 2-chloro-5-nitrobenzanilide 21-27 peroxisome proliferator activated receptor gamma Mus musculus 0-9 34744713-4 2021 Materials and Methods: Lipopolysaccharide (LPS) was used to activate primary microglia, which were then treated with different doses of Phi or the peroxisome proliferator-activated receptor-gamma (PPARgamma) antagonist (GW9662). 2-chloro-5-nitrobenzanilide 220-226 peroxisome proliferator activated receptor gamma Mus musculus 197-206 34744713-12 2021 The PPARgamma antagonist GW9662 significantly repressed Phi-mediated anti-inflammatory effects. 2-chloro-5-nitrobenzanilide 25-31 peroxisome proliferator activated receptor gamma Mus musculus 4-13 34372875-10 2021 Immunofluorescence examination demonstrated that GRb1 induced a pro-neurogenic phenotype of microglia via activating PPARgamma in vivo and in vitro, which were effectively reversed by the PPARgamma inhibitor GW9662. 2-chloro-5-nitrobenzanilide 208-214 peroxisome proliferator activated receptor gamma Mus musculus 117-126 34175325-7 2021 Importantly, co-administration of a PPARgamma antagonist GW9662 abrogated these protective effects of 15d-PGJ2. 2-chloro-5-nitrobenzanilide 57-63 peroxisome proliferator activated receptor gamma Mus musculus 36-45 34126188-12 2021 Furthermore, PPARgamma was also downregulated in vitro and in vivo, and its antagonist GW9662 reversed HOXA5-mediated inhibition of VSMC dedifferentiation and migration. 2-chloro-5-nitrobenzanilide 87-93 peroxisome proliferator activated receptor gamma Mus musculus 13-22 34580604-12 2021 In cultured proximal tubular cells, HG-induced PPARgamma and UCP2 expression was inhibited by PP2 or PPARgamma antagonist GW9662. 2-chloro-5-nitrobenzanilide 122-128 peroxisome proliferator activated receptor gamma Mus musculus 47-56 34580604-12 2021 In cultured proximal tubular cells, HG-induced PPARgamma and UCP2 expression was inhibited by PP2 or PPARgamma antagonist GW9662. 2-chloro-5-nitrobenzanilide 122-128 peroxisome proliferator activated receptor gamma Mus musculus 101-110 34372875-10 2021 Immunofluorescence examination demonstrated that GRb1 induced a pro-neurogenic phenotype of microglia via activating PPARgamma in vivo and in vitro, which were effectively reversed by the PPARgamma inhibitor GW9662. 2-chloro-5-nitrobenzanilide 208-214 peroxisome proliferator activated receptor gamma Mus musculus 188-197 34267342-8 2022 Besides, we demonstrated that bergenin (3, 10, and 30 muM) concentration-dependently activated PPARgamma in naive T cells, whereas PPARgamma antagonist GW9662 and siPPARgamma abolished bergenin-caused inhibition on glutaminolysis and Th17 differentiation. 2-chloro-5-nitrobenzanilide 152-158 peroxisome proliferator activated receptor gamma Mus musculus 131-140 34240269-8 2021 In addition, cotreatment with GW9662 (an antagonist of PPARgamma) effectively blocked these neuroprotective effects of BEOV, which provided strong evidence that PPARgamma-dependent signaling plays a key role in protecting against ER stress and neuronal apoptosis in AD. 2-chloro-5-nitrobenzanilide 30-36 peroxisome proliferator activated receptor gamma Mus musculus 55-64 34240269-8 2021 In addition, cotreatment with GW9662 (an antagonist of PPARgamma) effectively blocked these neuroprotective effects of BEOV, which provided strong evidence that PPARgamma-dependent signaling plays a key role in protecting against ER stress and neuronal apoptosis in AD. 2-chloro-5-nitrobenzanilide 30-36 peroxisome proliferator activated receptor gamma Mus musculus 161-170 35192884-12 2022 To further confirm the role of PPARgamma in TPhP mediated placental toxicity, pregnant mice were orally exposed to TPhP (1 mg/kg) or TPhP (1 mg/kg) + GW9662 (PPARgamma inhibitor, 2 mg/kg) from E0 until delivery. 2-chloro-5-nitrobenzanilide 150-156 peroxisome proliferator activated receptor gamma Mus musculus 158-167 35472412-2 2022 Pioglitazone-induced activation of PPAR-gamma for 12 weeks in db/db obese diabetic mice increases bodyweights and reduces blood glucose levels, but PPAR-gamma inhibition by 2-chloro-5-nitro-N-phenylbenzamide does not alter these parameters; instead, improves testis and epididymis weights and sperm count. 2-chloro-5-nitrobenzanilide 173-207 peroxisome proliferator activated receptor gamma Mus musculus 148-158 35610721-12 2022 GW9662 treatment prevented the nuclear transfer of PPAR-gamma in asperosaponin VI-treated microglia and inhibited the induction of Arg-1+ microglia. 2-chloro-5-nitrobenzanilide 0-6 peroxisome proliferator activated receptor gamma Mus musculus 51-61 34124763-7 2021 PPARgamma inhibitor GW9662 could eliminate the effect of BEOV on Abeta-induced NF-kappaB activation and proinflammatory mediator production. 2-chloro-5-nitrobenzanilide 20-26 peroxisome proliferator activated receptor gamma Mus musculus 0-9 34159197-7 2021 GW9662 was administrated to block the function of peroxisome proliferator-activated receptor gamma (PPAR-gamma). 2-chloro-5-nitrobenzanilide 0-6 peroxisome proliferator activated receptor gamma Mus musculus 50-98 34159197-15 2021 Moreover, GW9662, an inhibitor of PPAR-gamma, abolished the protective effect of emodin. 2-chloro-5-nitrobenzanilide 10-16 peroxisome proliferator activated receptor gamma Mus musculus 34-44 35610721-6 2022 In some experiments, stressed animals were treated with the PPAR-gamma antagonist GW9662 to examine its involvement in the effects of asperosaponin VI. 2-chloro-5-nitrobenzanilide 82-88 peroxisome proliferator activated receptor gamma Mus musculus 60-70 35192884-13 2022 The results showed that GW9662 could ameliorate the effect of TPhP on placental lipid accumulation, ERS and cell apoptosis, suggesting that PPARgamma mediated the placental toxicity of TPhP. 2-chloro-5-nitrobenzanilide 24-30 peroxisome proliferator activated receptor gamma Mus musculus 140-149 35192202-9 2022 Importantly, all of these protective effects mediated by GP-75 were abolished by cotreatment with the PPARgamma antagonist, GW9662. 2-chloro-5-nitrobenzanilide 124-130 peroxisome proliferator activated receptor gamma Mus musculus 102-111 35384292-4 2022 More importantly, QU markedly limited the development of Th17 cell polarization, which was virtually compromised by the treatment with peroxisome proliferator activated receptor gamma (PPARgamma) inhibitor GW9662 and knockdown of PPARgamma. 2-chloro-5-nitrobenzanilide 206-212 peroxisome proliferator activated receptor gamma Mus musculus 135-183 35384292-4 2022 More importantly, QU markedly limited the development of Th17 cell polarization, which was virtually compromised by the treatment with peroxisome proliferator activated receptor gamma (PPARgamma) inhibitor GW9662 and knockdown of PPARgamma. 2-chloro-5-nitrobenzanilide 206-212 peroxisome proliferator activated receptor gamma Mus musculus 185-194 35379352-7 2022 In addition, we treated mice of vestibular dysfunction with Betahistine (10 mg/Kg) and/or ERK inhibitor of SCH772984 (12 mg/Kg) and/or and PPARgamma antagonist GW9662 (1 mg/Kg) for 15 days, and evaluated the accuracy of air righting reflex, the time of contact righting reflex and the scores of head tilt and swimming behavior. 2-chloro-5-nitrobenzanilide 160-166 peroxisome proliferator activated receptor gamma Mus musculus 139-148 35441580-12 2022 GW9662 (an inhibitor of PPARgamma) or Erastin (an inducer of ferroptosis) partially weakened the suppressive effects of BMS309403 on HG-induced lipid peroxidation, oxidative stress and ferroptosis. 2-chloro-5-nitrobenzanilide 0-6 peroxisome proliferator activated receptor gamma Mus musculus 24-33 35245615-7 2022 Pre-treatment with the PPARgamma antagonist GW9662 reduced these increases. 2-chloro-5-nitrobenzanilide 44-50 peroxisome proliferator activated receptor gamma Mus musculus 23-32 35152284-4 2022 The facilitation of l-LTP induced by TB was blocked both by GW9662 (a PPARgamma antagonist) and C-Compound (an AMPK inhibitor), suggesting the involvement of both PPARgamma and AMPK on TB effects. 2-chloro-5-nitrobenzanilide 60-66 peroxisome proliferator activated receptor gamma Mus musculus 70-79 35433953-5 2022 GW9662 and pioglitazone were applied to inhibit and activate the PPARgamma, respectively. 2-chloro-5-nitrobenzanilide 0-6 peroxisome proliferator activated receptor gamma Mus musculus 65-74 35246845-7 2022 To further explore whether PPARgamma was involved in the anti-UC effect of ZO, PPARgamma inhibitor GW9662 was used. 2-chloro-5-nitrobenzanilide 99-105 peroxisome proliferator activated receptor gamma Mus musculus 79-88 35152284-4 2022 The facilitation of l-LTP induced by TB was blocked both by GW9662 (a PPARgamma antagonist) and C-Compound (an AMPK inhibitor), suggesting the involvement of both PPARgamma and AMPK on TB effects. 2-chloro-5-nitrobenzanilide 60-66 peroxisome proliferator activated receptor gamma Mus musculus 163-172 33161473-10 2021 The experiments using PPAR-gamma-specific inhibitor GW9662 and transient transfection with mutated PPAR-gamma-binding site promotor constructs showed that the activation of PPAR-gamma mediated CA-induced ADPN expression in adipocytes. 2-chloro-5-nitrobenzanilide 52-58 peroxisome proliferator activated receptor gamma Mus musculus 22-32 35072290-7 2022 PPAR-gamma antagonist GW9662 further enhanced IL-6 and TNF-alpha levels and decreased cell viability in the presence of LPS treatment. 2-chloro-5-nitrobenzanilide 22-28 peroxisome proliferator activated receptor gamma Mus musculus 0-10 34048863-11 2021 Pretreatment with the PPARgamma antagonist GW9662 (2 mg/kg/daily) blocked the behavioral effects of CBD. 2-chloro-5-nitrobenzanilide 43-49 peroxisome proliferator activated receptor gamma Mus musculus 22-31 33717177-8 2021 PPARgamma activity is suppressed by application of its antagonist GW9662 or shRNA. 2-chloro-5-nitrobenzanilide 66-72 peroxisome proliferator activated receptor gamma Mus musculus 0-9 33654384-7 2021 In vitro, RAW264.7 macrophages stimulated with ox-LDL were treated with CNT (50 or 100 nM) for 24 h. The specific PPARgamma antagonist, GW9662, was used to block the PPARgamma signaling pathway in vitro. 2-chloro-5-nitrobenzanilide 136-142 peroxisome proliferator activated receptor gamma Mus musculus 114-123 33654384-7 2021 In vitro, RAW264.7 macrophages stimulated with ox-LDL were treated with CNT (50 or 100 nM) for 24 h. The specific PPARgamma antagonist, GW9662, was used to block the PPARgamma signaling pathway in vitro. 2-chloro-5-nitrobenzanilide 136-142 peroxisome proliferator activated receptor gamma Mus musculus 166-175 33296744-4 2021 Initially, the optimal doses of LPS, RGZ and GW9662 (a potent and selective PPARgamma antagonist) were determined by treating the mouse zygotes up to blastocyst stage and assessment of compaction and blastocyst rates. 2-chloro-5-nitrobenzanilide 45-51 peroxisome proliferator activated receptor gamma Mus musculus 76-85 33296744-10 2021 Through immunostaining, it was shown that LPS could prevent the translocation of PPARgamma to nucleus; and translocation was facilitated by RGZ and this effect was reversed by GW9662. 2-chloro-5-nitrobenzanilide 176-182 peroxisome proliferator activated receptor gamma Mus musculus 81-90 35151213-12 2022 In the culture of primary neurons, addition of PPARgamma inhibitor GW9662 eliminated the effects of EsA on AD pathologies. 2-chloro-5-nitrobenzanilide 67-73 peroxisome proliferator activated receptor gamma Mus musculus 47-56 33205365-11 2021 The majority of the effects were attenuated in presence of PPAR-gamma antagonist (GW9662). 2-chloro-5-nitrobenzanilide 82-88 peroxisome proliferator activated receptor gamma Mus musculus 59-69 33684197-3 2021 We observed increased protein NF-kappaB expression in mouse brain tissue using GW9662, which is the specific antagonist of PPARgamma, in a mouse model of angiostrongyliasis. 2-chloro-5-nitrobenzanilide 79-85 peroxisome proliferator activated receptor gamma Mus musculus 123-132 32805581-6 2020 Intraperitoneal administration of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) inhibitor GW9662 was given 30 mins before MaR1. 2-chloro-5-nitrobenzanilide 106-112 peroxisome proliferator activated receptor gamma Mus musculus 34-82 32359341-8 2021 Further, we confirmed that BCA mediated inhibitory effects are mediated through PPARgamma as assessed by treatment with PPARgamma antagonist GW9662. 2-chloro-5-nitrobenzanilide 141-147 peroxisome proliferator activated receptor gamma Mus musculus 80-89 32359341-8 2021 Further, we confirmed that BCA mediated inhibitory effects are mediated through PPARgamma as assessed by treatment with PPARgamma antagonist GW9662. 2-chloro-5-nitrobenzanilide 141-147 peroxisome proliferator activated receptor gamma Mus musculus 120-129 33338634-6 2021 We also found CBGA-Q and CBGA-Q-Salt being cytoprotective in this cell assay, but their effects were completely eliminated by GW9662, thus indicating that they are active at the canonical site in the PPAR-gamma receptor. 2-chloro-5-nitrobenzanilide 126-132 peroxisome proliferator activated receptor gamma Mus musculus 200-210 32805581-6 2020 Intraperitoneal administration of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) inhibitor GW9662 was given 30 mins before MaR1. 2-chloro-5-nitrobenzanilide 106-112 peroxisome proliferator activated receptor gamma Mus musculus 84-94 32805581-11 2020 The pretreatment with PPAR-gamma antagonist GW9662 could significantly suppress the polarization of M2 macrophages and antagonize the protective effects of MaR1 on LPS-stimulated ALI. 2-chloro-5-nitrobenzanilide 44-50 peroxisome proliferator activated receptor gamma Mus musculus 22-32 31889120-7 2019 Treatment with mTOR inhibitor rapamycin or PPARgamma inhibitor GW9662 suppressed lipid droplets and PGE2 secretion. 2-chloro-5-nitrobenzanilide 63-69 peroxisome proliferator activated receptor gamma Mus musculus 43-52 33082908-8 2020 Importantly, the protective effect of SHTL in the LPS- and Ox-LDL-induced macrophages against inflammation and lipid accumulation was attenuated by GW9662, a PPAR-gamma antagonist, which confirmed the prediction results of network pharmacology. 2-chloro-5-nitrobenzanilide 148-154 peroxisome proliferator activated receptor gamma Mus musculus 158-168 32652815-6 2020 In addition, the improved effect of TP5 on survival rates was abolished by the peroxisome proliferator-activated receptor gamma (PPARgamma) antagonist GW9662. 2-chloro-5-nitrobenzanilide 151-157 peroxisome proliferator activated receptor gamma Mus musculus 79-127 32652815-6 2020 In addition, the improved effect of TP5 on survival rates was abolished by the peroxisome proliferator-activated receptor gamma (PPARgamma) antagonist GW9662. 2-chloro-5-nitrobenzanilide 151-157 peroxisome proliferator activated receptor gamma Mus musculus 129-138 32821266-8 2020 However, intervention of GW9662, PPARgamma antagonist, attenuated Rb1-mediated effects on glycolipid metabolism and AQP7 levels. 2-chloro-5-nitrobenzanilide 25-31 peroxisome proliferator activated receptor gamma Mus musculus 33-42 31758207-4 2020 After pretreatment with BML-111 or GW9662, the apigenin-induced nucleus Nrf-2 or intracellular PPARgamma protein expressions were completely inhibited, respectively, but the both pretreatment differently affected the protective effect of apigenin on hepatocytes. 2-chloro-5-nitrobenzanilide 35-41 peroxisome proliferator activated receptor gamma Mus musculus 95-104 32412807-11 2020 However, treatment with the PPARgamma antagonist GW9662 partially reversed the protective effects of atorvastatin. 2-chloro-5-nitrobenzanilide 49-55 peroxisome proliferator activated receptor gamma Mus musculus 28-37 32226299-4 2020 We previously showed that pharmacologic inhibition of PPARgamma by GW9662 boosts alphaPD-L1 and alphaPD-1 antibody efficacy in treating murine mammary tumors. 2-chloro-5-nitrobenzanilide 67-73 peroxisome proliferator activated receptor gamma Mus musculus 54-63 32016452-6 2020 This effect was terminated by cotreatment with GW9662, a PPARgamma antagonist. 2-chloro-5-nitrobenzanilide 47-53 peroxisome proliferator activated receptor gamma Mus musculus 57-66 32248343-5 2020 However, inhibition of lipid oxidation using GW9662 (an inhibitor of PPAR-gamma) and GW6471 (an inhibitor of PPAR-alpha) abolished the anti-inflammatory effect of PPC. 2-chloro-5-nitrobenzanilide 45-51 peroxisome proliferator activated receptor gamma Mus musculus 69-79 31634455-8 2020 These anti-inflammatory effects were antagonized by PPARgamma inhibitor GW9662. 2-chloro-5-nitrobenzanilide 72-78 peroxisome proliferator activated receptor gamma Mus musculus 52-61 31634455-9 2020 In addition, telmisartan increased the expression of PTEN (phosphate and tensin homolog deleted on chromosome 10), a lipid and protein phosphatase; PPARgamma inhibitor GW9662 reversed this effect, indicating that telmisartan-induced PTEN expression is PPARgamma dependent. 2-chloro-5-nitrobenzanilide 168-174 peroxisome proliferator activated receptor gamma Mus musculus 148-157 31634455-9 2020 In addition, telmisartan increased the expression of PTEN (phosphate and tensin homolog deleted on chromosome 10), a lipid and protein phosphatase; PPARgamma inhibitor GW9662 reversed this effect, indicating that telmisartan-induced PTEN expression is PPARgamma dependent. 2-chloro-5-nitrobenzanilide 168-174 peroxisome proliferator activated receptor gamma Mus musculus 252-261 33100875-10 2020 The anti-inflammatory effects of ASA VI in microglia were blocked by treating PPAR-gamma antagonist (GW9662). 2-chloro-5-nitrobenzanilide 101-107 peroxisome proliferator activated receptor gamma Mus musculus 78-88 32845434-10 2020 Furthermore, the protective effect of PDX on lung tissue could be reversed by GW9662, a specific PPAR-gamma antagonist. 2-chloro-5-nitrobenzanilide 78-84 peroxisome proliferator activated receptor gamma Mus musculus 97-107 32945426-3 2020 PPAR-gamma was activated by rosiglitazone, and was inhibited by GW9662. 2-chloro-5-nitrobenzanilide 64-70 peroxisome proliferator activated receptor gamma Mus musculus 0-10 32945426-10 2020 When PPAR-gamma was activated, pmTOR and pS6K protein expression levels were significantly decreased, and the mRNA expression levels of TNF-alpha and IL-1beta were significantly reduced, but this inhibition could be alleviated by administrating GW9662. 2-chloro-5-nitrobenzanilide 245-251 peroxisome proliferator activated receptor gamma Mus musculus 5-15 32918259-10 2021 The effects of wogonin were abolished by administration of the PPAR-gamma inhibitor GW9662. 2-chloro-5-nitrobenzanilide 84-90 peroxisome proliferator activated receptor gamma Mus musculus 63-73 31846359-10 2020 However, GW9662 significantly reduced this effect, indicating that PPAR-gamma is a critical mediator in the rhein-mediated anti-inflammatory process. 2-chloro-5-nitrobenzanilide 9-15 peroxisome proliferator activated receptor gamma Mus musculus 67-77 32290308-9 2020 GW9662, a peroxisome proliferator-activated receptor-gamma (PPARgamma) antagonist, suppressed PGD2-induced neurite outgrowth. 2-chloro-5-nitrobenzanilide 0-6 peroxisome proliferator activated receptor gamma Mus musculus 10-58 32290308-9 2020 GW9662, a peroxisome proliferator-activated receptor-gamma (PPARgamma) antagonist, suppressed PGD2-induced neurite outgrowth. 2-chloro-5-nitrobenzanilide 0-6 peroxisome proliferator activated receptor gamma Mus musculus 60-69 31812418-7 2020 Furthermore, the preadipocytes differentiation was blocked by the PPARgamma-specific antagonist GW9662, indicating that the PPARgamma signaling pathway plays an important part in 3T3-L1 cell differentiation induced by EHDPP. 2-chloro-5-nitrobenzanilide 96-102 peroxisome proliferator activated receptor gamma Mus musculus 66-75 31812418-7 2020 Furthermore, the preadipocytes differentiation was blocked by the PPARgamma-specific antagonist GW9662, indicating that the PPARgamma signaling pathway plays an important part in 3T3-L1 cell differentiation induced by EHDPP. 2-chloro-5-nitrobenzanilide 96-102 peroxisome proliferator activated receptor gamma Mus musculus 124-133 31770568-5 2020 PPARg blockage by treatment with GW9662 nullified pioglitazone"s effect on systemic and muscle insulin sensitivity and citrate synthase activity of obese mice. 2-chloro-5-nitrobenzanilide 33-39 peroxisome proliferator activated receptor gamma Mus musculus 0-5 31741264-10 2020 Meanwhile, the qRT-PCR results revealed that the LPS-induced upregulation of Ar mRNA in MLTC1 cells and Erbeta mRNA in TM4 cells were significantly recovered after treatment with the specific PPARgamma-antagonist GW9662. 2-chloro-5-nitrobenzanilide 213-219 peroxisome proliferator activated receptor gamma Mus musculus 192-201 31749335-8 2020 These effects of CYP2J2/EET were partially blocked by GW9662, the antagonist of PPAR-gamma. 2-chloro-5-nitrobenzanilide 54-60 peroxisome proliferator activated receptor gamma Mus musculus 80-90 31756041-9 2019 We further found that the expression of Arg-1 was also upregulated in those tPA and RSG-treated stroke mice and the protection against tPA-induced HT and BBB disruption in these mice were abolished in the presence of PPAR-gamma antagonist GW9662 (4 mg/kg, 1 hour before dMCAO through intraperitoneal injection). 2-chloro-5-nitrobenzanilide 239-245 peroxisome proliferator activated receptor gamma Mus musculus 217-227 31426846-13 2019 Further analysis showed that the effect of MSC + DAC on macrophage polarization was largely abrogated by the peroxisome proliferator-activated receptor gamma (PPARgamma) antagonist GW9662. 2-chloro-5-nitrobenzanilide 181-187 peroxisome proliferator activated receptor gamma Mus musculus 109-157 30742088-10 2019 Importantly, PPARgamma inhibition by GW9662 reversed the HSPA12A-mediated adipocyte differentiation. 2-chloro-5-nitrobenzanilide 37-43 peroxisome proliferator activated receptor gamma Mus musculus 13-22 30842627-8 2019 PPARgamma antagonist GW9662 reversed the signaling by PPARgamma/PTEN; the reduction in EMT-activating transcription factors, such as Snai1 and Zeb1; and the antimetastatic effect of the ApoSQ injection. 2-chloro-5-nitrobenzanilide 21-27 peroxisome proliferator activated receptor gamma Mus musculus 0-9 30842627-8 2019 PPARgamma antagonist GW9662 reversed the signaling by PPARgamma/PTEN; the reduction in EMT-activating transcription factors, such as Snai1 and Zeb1; and the antimetastatic effect of the ApoSQ injection. 2-chloro-5-nitrobenzanilide 21-27 peroxisome proliferator activated receptor gamma Mus musculus 54-63 31799666-16 2019 Furthermore, a PPARgamma antagonist (GW9662) and PTP inhibitor (NSC87877) abrogated the suppressive function of PPARgamma and PTPRF in FE1.2 cells, respectively. 2-chloro-5-nitrobenzanilide 37-43 peroxisome proliferator activated receptor gamma Mus musculus 15-24 31799666-16 2019 Furthermore, a PPARgamma antagonist (GW9662) and PTP inhibitor (NSC87877) abrogated the suppressive function of PPARgamma and PTPRF in FE1.2 cells, respectively. 2-chloro-5-nitrobenzanilide 37-43 peroxisome proliferator activated receptor gamma Mus musculus 112-121 31437794-5 2019 Antagonism of PPARgamma by GW9662 abrogated the effects of DHA on HSCs. 2-chloro-5-nitrobenzanilide 27-33 peroxisome proliferator activated receptor gamma Mus musculus 14-23 31426846-13 2019 Further analysis showed that the effect of MSC + DAC on macrophage polarization was largely abrogated by the peroxisome proliferator-activated receptor gamma (PPARgamma) antagonist GW9662. 2-chloro-5-nitrobenzanilide 181-187 peroxisome proliferator activated receptor gamma Mus musculus 159-168 30565728-5 2019 Importantly, we observed that forced expression of TLR4 or blocked PPAR-gamma with the antagonist GW9662 effectively abolished Gal-3 inhibition-mediated anti-inflammatory and antiapoptosis effects triggered by LPS. 2-chloro-5-nitrobenzanilide 98-104 peroxisome proliferator activated receptor gamma Mus musculus 67-77 31064820-13 2019 Overexpression of miR-130a and PPARgamma antagonist GW9662 inhibited lipogenesis and TG secretion, and PPARgamma agonist GW1929 reversed this change induced by miR-130a up-regulation.Conclusion: Knockdown of H19 alleviated hepatic lipogenesis via directly regulating miR-130a/PPARgamma axis, which is a novel mechanistic role of H19 in the regulation of NAFLD. 2-chloro-5-nitrobenzanilide 52-58 peroxisome proliferator activated receptor gamma Mus musculus 31-40 30084995-8 2019 This effect was abrogated by pre-treatment with the PPARgamma antagonist GW9662. 2-chloro-5-nitrobenzanilide 73-79 peroxisome proliferator activated receptor gamma Mus musculus 52-61 30700583-10 2019 Addition of the PPAR-gamma antagonist GW 9662 abrogated the effects of AC in vitro. 2-chloro-5-nitrobenzanilide 38-45 peroxisome proliferator activated receptor gamma Mus musculus 16-26 30735218-5 2019 After the preincubation of isoproterenol-stimulated cardiac fibroblasts with the PPARgamma antagonist GW9662, stevioside-reduced protein expressions were decreased, but stevioside-induced Smad7 was not affected. 2-chloro-5-nitrobenzanilide 102-108 peroxisome proliferator activated receptor gamma Mus musculus 81-90 30105672-5 2019 Surprisingly, the PPARgamma antagonists GW9662 and T0070907 were neuroprotective and enhanced Telmisartan effects. 2-chloro-5-nitrobenzanilide 40-46 peroxisome proliferator activated receptor gamma Mus musculus 18-27 30472831-7 2018 PPARgamma inhibitor GW9662 largely abrogated the roles of naringin in vitro. 2-chloro-5-nitrobenzanilide 20-26 peroxisome proliferator activated receptor gamma Mus musculus 0-9 31620609-11 2019 Among ARBs, including losartan and fimasartan, only telmisartan changed IRS-1 phosphorylation and pretreatment with GW9662, a specific and irreversible peroxisome proliferator-activated receptor gamma (PPARgamma) antagonist, did not alter this effect. 2-chloro-5-nitrobenzanilide 116-122 peroxisome proliferator activated receptor gamma Mus musculus 152-200 31620609-11 2019 Among ARBs, including losartan and fimasartan, only telmisartan changed IRS-1 phosphorylation and pretreatment with GW9662, a specific and irreversible peroxisome proliferator-activated receptor gamma (PPARgamma) antagonist, did not alter this effect. 2-chloro-5-nitrobenzanilide 116-122 peroxisome proliferator activated receptor gamma Mus musculus 202-211 30566427-4 2018 We further show that PPARgamma is a direct substrate of Smurf1-mediated non-proteolytic lysine 63 (K63)-linked ubiquitin modification that suppresses its transcriptional activity, and treatment of Smurf1-deficient mice with a PPARgamma antagonist, GW9662, completely reversed the lipid accumulation in the liver. 2-chloro-5-nitrobenzanilide 248-254 peroxisome proliferator activated receptor gamma Mus musculus 21-30 30400642-6 2018 Interestingly, addition of the PPARgamma inhibitor, GW9662 further downregulated Foxp3 expression in these cells from both mice. 2-chloro-5-nitrobenzanilide 52-58 peroxisome proliferator activated receptor gamma Mus musculus 31-40 30223096-7 2018 The reversal effects of honokiol on behavioral impairment and striatal PPARgamma expression were impeded by PPARgamma antagonist GW9662. 2-chloro-5-nitrobenzanilide 129-135 peroxisome proliferator activated receptor gamma Mus musculus 71-80 30223096-7 2018 The reversal effects of honokiol on behavioral impairment and striatal PPARgamma expression were impeded by PPARgamma antagonist GW9662. 2-chloro-5-nitrobenzanilide 129-135 peroxisome proliferator activated receptor gamma Mus musculus 108-117 30056259-7 2018 Functional aspects were analyzed using PPAR-gamma specific inhibitor GW9662, which attenuated the LPS-induced secretion of proinflammatory mediators, such as TNF-alpha, IL-1beta, PGE2, and NO. 2-chloro-5-nitrobenzanilide 69-75 peroxisome proliferator activated receptor gamma Mus musculus 39-49 30217539-15 2018 Pretreatment with the PPARgamma antagonist, GW9662, blocked the behavioural effect of CBD in our TD model. 2-chloro-5-nitrobenzanilide 44-50 peroxisome proliferator activated receptor gamma Mus musculus 22-31 29991481-5 2018 Honokiol increased the transcriptional activity and protein levels of peroxisome proliferator-activated receptor-gamma (PPARgamma) However, all of the beneficial effects of honokiol on pathologic changes, including biochemistry and cognitive function, could be blocked by GW9662, a specific PPARgamma inhibitor. 2-chloro-5-nitrobenzanilide 272-278 peroxisome proliferator activated receptor gamma Mus musculus 70-118 29383561-7 2018 Furthermore, betaine combined with PPARgamma inhibitor GW9662 treatment showed that betaine elevated C2C12 lipid accumulation through upregulation of PPARgamma. 2-chloro-5-nitrobenzanilide 55-61 peroxisome proliferator activated receptor gamma Mus musculus 35-44 29383561-7 2018 Furthermore, betaine combined with PPARgamma inhibitor GW9662 treatment showed that betaine elevated C2C12 lipid accumulation through upregulation of PPARgamma. 2-chloro-5-nitrobenzanilide 55-61 peroxisome proliferator activated receptor gamma Mus musculus 150-159 29648978-7 2018 In addition, the specific FGFR1 and peroxisome proliferator-activated receptor gamma (PPARgamma) inhibitors PD173074 and GW9662, respectively, were applied to further explore the possible mechanism of rhFGF21 in BBB maintenance after TBI. 2-chloro-5-nitrobenzanilide 121-127 peroxisome proliferator activated receptor gamma Mus musculus 86-95 29991481-5 2018 Honokiol increased the transcriptional activity and protein levels of peroxisome proliferator-activated receptor-gamma (PPARgamma) However, all of the beneficial effects of honokiol on pathologic changes, including biochemistry and cognitive function, could be blocked by GW9662, a specific PPARgamma inhibitor. 2-chloro-5-nitrobenzanilide 272-278 peroxisome proliferator activated receptor gamma Mus musculus 120-129 29991481-5 2018 Honokiol increased the transcriptional activity and protein levels of peroxisome proliferator-activated receptor-gamma (PPARgamma) However, all of the beneficial effects of honokiol on pathologic changes, including biochemistry and cognitive function, could be blocked by GW9662, a specific PPARgamma inhibitor. 2-chloro-5-nitrobenzanilide 272-278 peroxisome proliferator activated receptor gamma Mus musculus 291-300 29631101-10 2018 Conversely, the selective PPARgamma antagonist GW9662 reversed the influence of PB in macrophages. 2-chloro-5-nitrobenzanilide 47-53 peroxisome proliferator activated receptor gamma Mus musculus 26-35 29359338-9 2018 GW9662, a PPAR-gamma antagonist, significantly blocked the antidepressant-like effect of pioglitazone. 2-chloro-5-nitrobenzanilide 0-6 peroxisome proliferator activated receptor gamma Mus musculus 10-20 29867472-7 2018 In addition, PPARgamma antagonist GW9662 co-administration mostly blocked these effects, suggesting the important role of PPARgamma pathways in mediating 20(S)-Rg3 effects in macrophage polarization and atherosclerosis progression. 2-chloro-5-nitrobenzanilide 34-40 peroxisome proliferator activated receptor gamma Mus musculus 13-22 30236201-5 2018 Furthermore, the role of PPARgamma in the regulation of inflammatory-related NF-kappaB and MAPK signaling pathways was analyzed using GW9662 (5 mumol/L) which was a highly irreversible PPARgamma antagonist. 2-chloro-5-nitrobenzanilide 134-140 peroxisome proliferator activated receptor gamma Mus musculus 25-34 30236201-5 2018 Furthermore, the role of PPARgamma in the regulation of inflammatory-related NF-kappaB and MAPK signaling pathways was analyzed using GW9662 (5 mumol/L) which was a highly irreversible PPARgamma antagonist. 2-chloro-5-nitrobenzanilide 134-140 peroxisome proliferator activated receptor gamma Mus musculus 185-194 29867472-7 2018 In addition, PPARgamma antagonist GW9662 co-administration mostly blocked these effects, suggesting the important role of PPARgamma pathways in mediating 20(S)-Rg3 effects in macrophage polarization and atherosclerosis progression. 2-chloro-5-nitrobenzanilide 34-40 peroxisome proliferator activated receptor gamma Mus musculus 122-131 29367091-8 2018 Meanwhile, PPAR-gamma inhibitor GW9662 was performed to knockdown PPAR-gamma expression in cells. 2-chloro-5-nitrobenzanilide 32-38 peroxisome proliferator activated receptor gamma Mus musculus 11-21 29367091-8 2018 Meanwhile, PPAR-gamma inhibitor GW9662 was performed to knockdown PPAR-gamma expression in cells. 2-chloro-5-nitrobenzanilide 32-38 peroxisome proliferator activated receptor gamma Mus musculus 66-76 29367091-10 2018 Furthermore, our data also figured out that these effects of chrysophanol were largely abrogated by PPAR-gamma inhibitor GW9662. 2-chloro-5-nitrobenzanilide 121-127 peroxisome proliferator activated receptor gamma Mus musculus 100-110 29369796-10 2018 The inhibition of asiatic acid on inflammatory mediators production were prevented by PPARgamma inhibitor, GW9662. 2-chloro-5-nitrobenzanilide 107-113 peroxisome proliferator activated receptor gamma Mus musculus 86-95 28670854-12 2018 Furthermore, honokiol (10 muM) treatment in mouse peritoneal cells, RAW264.7 cells and ANA-1 cells, led to M2 macrophage polarization, whereas a PPARgamma antagonist, GW9662, abolished this effect of honokiol. 2-chloro-5-nitrobenzanilide 167-173 peroxisome proliferator activated receptor gamma Mus musculus 145-154 29160030-8 2018 Inhibition of PPARgamma activity with GW9662 potently blocked DHM-induced glucose uptake and adiponectin secretion. 2-chloro-5-nitrobenzanilide 38-44 peroxisome proliferator activated receptor gamma Mus musculus 14-23 29275517-8 2018 PPARgamma antagonist GW9662 (20 mumol/L) pretreatment reversed the effect of Sar on BACE1 protein expression in HG-cultured HT-22 cells. 2-chloro-5-nitrobenzanilide 21-27 peroxisome proliferator activated receptor gamma Mus musculus 0-9 28391584-11 2017 PPARgamma antagonist (GW9662 10 muM) decreased the expression of SGLT2 and increased glucagon as HG did. 2-chloro-5-nitrobenzanilide 22-28 peroxisome proliferator activated receptor gamma Mus musculus 0-9 29310116-9 2018 A selective antagonist of PPAR-gamma, GW9662, neutralized the anti-fibrotic effect and abolished the inhibitory effect of EndMT during the treatment of PIO. 2-chloro-5-nitrobenzanilide 38-44 peroxisome proliferator activated receptor gamma Mus musculus 26-36 29278639-4 2017 Pioglitazone (20 mg/kg/d) or PPAR-gamma inhibitor GW9662 (1 mg/kg/d) were administered for 12 weeks. 2-chloro-5-nitrobenzanilide 50-56 peroxisome proliferator activated receptor gamma Mus musculus 29-39 29278639-13 2017 Blockade of PPAR-gamma activity by GW9662 remarkably attenuated the inhibitory actions of pioglitazone on atherogenesis, both in diabetic ApoE-/- mice and in cultured VSMCs, upon high-glucose challenge. 2-chloro-5-nitrobenzanilide 35-41 peroxisome proliferator activated receptor gamma Mus musculus 12-22 28849019-10 2017 However, the effects of LCE were reversed by cotreatment with the PPARgamma inhibitor GW9662. 2-chloro-5-nitrobenzanilide 86-92 peroxisome proliferator activated receptor gamma Mus musculus 66-75 29367637-10 2018 Small interfering RNA against Ppar-gamma (siPpar-gamma) and GW9662, a specific antagonist of PPAR-gamma, abolished RA-mediated AMPKalpha phosphorylation and alleviation of fibrotic response in vitro. 2-chloro-5-nitrobenzanilide 60-66 peroxisome proliferator activated receptor gamma Mus musculus 93-103 28631352-9 2017 The effects of Ad-STAMP2 transfection on HUVECs were abolished by treatment with PPARgamma antagonist GW9662 (2.5 muM), and the roles of STAMP2 siRNA on HUVECs were also reversed by treatment with PPARgamma agonist rosiglitazone (RSG) (0.1 mM). 2-chloro-5-nitrobenzanilide 102-108 peroxisome proliferator activated receptor gamma Mus musculus 81-90 29020973-15 2017 Further experiments, treating melanoma cell lines with alphaMSH in the presence/absence of GW9662, as an inhibitor of PPARgamma, confirmed the key role of this transcription factor in decreasing cell proliferation in response to the hormone exposure. 2-chloro-5-nitrobenzanilide 91-97 peroxisome proliferator activated receptor gamma Mus musculus 118-127 29156799-8 2017 Conversely, pharmacological inhibition of PPARgamma by GW9662 abolished the protective effects of AA on hepatic I/R injury and in turn aggravated NLRP3 inflammasome activation. 2-chloro-5-nitrobenzanilide 55-61 peroxisome proliferator activated receptor gamma Mus musculus 42-51 28801611-5 2017 Moreover, PB inhibited the phosphorylation of IkappaBalpha and miR-155 expression both in NC/Nga mice and in IL-17-stimulated RAW264.7 cells, which could be reversed by GW9662, a specific antagonist for PPARgamma. 2-chloro-5-nitrobenzanilide 169-175 peroxisome proliferator activated receptor gamma Mus musculus 203-212 28595081-8 2017 The beneficial effects of PIO, at both the behavioral and molecular level, were significantly inhibited by the PPAR-gamma specific antagonist GW9662. 2-chloro-5-nitrobenzanilide 142-148 peroxisome proliferator activated receptor gamma Mus musculus 111-121 28112878-9 2017 The antinociceptive effect of thiazolidinones was prevented by GW9662, a PPARgamma antagonist. 2-chloro-5-nitrobenzanilide 63-69 peroxisome proliferator activated receptor gamma Mus musculus 73-82 28437481-12 2017 Furthermore, we show that TPP- and IPTP-dependent upregulation of aP2 was significantly inhibited by the selective PPARgamma antagonist GW9662. 2-chloro-5-nitrobenzanilide 136-142 peroxisome proliferator activated receptor gamma Mus musculus 115-124 27956741-9 2017 Moreover, pretreatment with the PPARgamma-selective antagonist GW9662 blocked rosiglitazone-induced adiponectin expression and antidepressant/anxiolytic-like effects. 2-chloro-5-nitrobenzanilide 63-69 peroxisome proliferator activated receptor gamma Mus musculus 32-41 28410218-10 2017 Moreover, inhibition of PPAR-gamma by GW9662 could prevent the inhibition of 6-Shogaol on LPS-induced inflammatory mediator production. 2-chloro-5-nitrobenzanilide 38-44 peroxisome proliferator activated receptor gamma Mus musculus 24-34 28216619-11 2017 Pretreatment with the PPARgamma receptor blocker GW9662 (2 mug, ip) partly reversed the protective effects of 15d-PGJ2 on hepatic I/R injury. 2-chloro-5-nitrobenzanilide 49-55 peroxisome proliferator activated receptor gamma Mus musculus 22-31 27023226-13 2017 GW9662, which is a PPARgamma antagonist, significantly blocked the beneficial role of AS-IV. 2-chloro-5-nitrobenzanilide 0-6 peroxisome proliferator activated receptor gamma Mus musculus 19-28 28423012-8 2017 Accordingly, we observed that the PPAR-gamma antagonist, GW9662, reversed the effect of 15-keto-PGE2 in Kupffer cell in vitro and restored the susceptibility of 15-PGDH Tg mice to LPS/GalN-induced acute liver injury in vivo. 2-chloro-5-nitrobenzanilide 57-63 peroxisome proliferator activated receptor gamma Mus musculus 34-44 28303415-6 2017 In addition, the inhibition of Sch B on TNF-alpha, IL-6, IL-1beta, and PGE2 production were reversed by PPAR-gamma antagonist GW9662. 2-chloro-5-nitrobenzanilide 126-132 peroxisome proliferator activated receptor gamma Mus musculus 104-114 28262343-8 2017 The anti-inflammation effect of PEDF was attenuated by PPAR-gamma specific antagonist GW9662. 2-chloro-5-nitrobenzanilide 86-92 peroxisome proliferator activated receptor gamma Mus musculus 55-65 28207769-5 2017 GW9662 (GW), a selective PPAR-gamma inhibitor, was also administered by intraperitoneal injection at the dose of 1 mg/kg/day combined with GED treatment. 2-chloro-5-nitrobenzanilide 0-6 peroxisome proliferator activated receptor gamma Mus musculus 25-35 28115365-5 2017 GW9662, a potent PPARgamma antagonist, blocked the antileukemic effect of selenium supplementation by significantly reducing CyPGs. 2-chloro-5-nitrobenzanilide 0-6 peroxisome proliferator activated receptor gamma Mus musculus 17-26 28330809-10 2017 Pretreatment with GW9662, a specific inhibitor of peroxisome proliferator activated receptor-gamma (PPAR-gamma), reversed the effect elicited by piperine in vitro. 2-chloro-5-nitrobenzanilide 18-24 peroxisome proliferator activated receptor gamma Mus musculus 100-110 27940378-8 2017 However, these beneficial effects were abolished by the PPARgamma specific antagonist GW9662, suggesting a pivotal role of the PPARgamma pathway in the pathogenesis of POCD. 2-chloro-5-nitrobenzanilide 86-92 peroxisome proliferator activated receptor gamma Mus musculus 56-65 27940378-8 2017 However, these beneficial effects were abolished by the PPARgamma specific antagonist GW9662, suggesting a pivotal role of the PPARgamma pathway in the pathogenesis of POCD. 2-chloro-5-nitrobenzanilide 86-92 peroxisome proliferator activated receptor gamma Mus musculus 127-136 27840193-11 2016 These effects of ginsenoside Re on BACE1 could be effectively inhibited by the PPARgamma antagonist GW9662. 2-chloro-5-nitrobenzanilide 100-106 peroxisome proliferator activated receptor gamma Mus musculus 79-88 27810934-7 2016 The administration of GW9662, a selective PPARgamma antagonist, elicited a marked anxiogenic response in PPARgamma wild-type (WT), but not in PPARgammaNestinCre knock-out (KO) mice. 2-chloro-5-nitrobenzanilide 22-28 peroxisome proliferator activated receptor gamma Mus musculus 42-51 27810934-7 2016 The administration of GW9662, a selective PPARgamma antagonist, elicited a marked anxiogenic response in PPARgamma wild-type (WT), but not in PPARgammaNestinCre knock-out (KO) mice. 2-chloro-5-nitrobenzanilide 22-28 peroxisome proliferator activated receptor gamma Mus musculus 105-114 27527983-8 2017 GW9662, a PPARgamma antagonist, prevented KD-mediated changes in PPARgamma2 expression and prevented the anti-seizure efficacy of the KD in Kv1.1KO mice. 2-chloro-5-nitrobenzanilide 0-6 peroxisome proliferator activated receptor gamma Mus musculus 10-19 27527983-8 2017 GW9662, a PPARgamma antagonist, prevented KD-mediated changes in PPARgamma2 expression and prevented the anti-seizure efficacy of the KD in Kv1.1KO mice. 2-chloro-5-nitrobenzanilide 0-6 peroxisome proliferator activated receptor gamma Mus musculus 65-75 26582466-7 2016 Intriguingly, T4, like pioglitazone (a PPARgamma agonist), suppressed the BACE1 activity in N2a-APP695 cells, which was attenuated by GW9662 (a PPARgamma antagonist). 2-chloro-5-nitrobenzanilide 134-140 peroxisome proliferator activated receptor gamma Mus musculus 39-48 27181586-8 2016 Importantly, all effects induced by BBR were abolished by GW9662, an antagonist of peroxisome proliferator-activated receptor-gamma. 2-chloro-5-nitrobenzanilide 58-64 peroxisome proliferator activated receptor gamma Mus musculus 83-131 26582466-7 2016 Intriguingly, T4, like pioglitazone (a PPARgamma agonist), suppressed the BACE1 activity in N2a-APP695 cells, which was attenuated by GW9662 (a PPARgamma antagonist). 2-chloro-5-nitrobenzanilide 134-140 peroxisome proliferator activated receptor gamma Mus musculus 144-153 27273607-13 2016 Co-treatment of cells with the selective PPARgamma antagonist GW9662 inhibits BPS-, BPA-, ROSI- but not dexamethasone-dependent adipogenic differentiation. 2-chloro-5-nitrobenzanilide 62-68 peroxisome proliferator activated receptor gamma Mus musculus 41-50 27373852-7 2016 Inhibition of PPAR-gamma by GW9662 restored the suppression of activated PPAR-gamma on phosphorylation of AKT and subsequent skp2 production. 2-chloro-5-nitrobenzanilide 28-34 peroxisome proliferator activated receptor gamma Mus musculus 14-24 27373852-7 2016 Inhibition of PPAR-gamma by GW9662 restored the suppression of activated PPAR-gamma on phosphorylation of AKT and subsequent skp2 production. 2-chloro-5-nitrobenzanilide 28-34 peroxisome proliferator activated receptor gamma Mus musculus 73-83 27716270-11 2016 The amelioration of the depression was blocked by the PPARgamma antagonist GW9662. 2-chloro-5-nitrobenzanilide 75-81 peroxisome proliferator activated receptor gamma Mus musculus 54-63 27540527-8 2016 Our results indicated that during CPC formation, PPARgamma inactivation via treatment with GW9662 (GW) reduced expression of CPC and cardiac markers. 2-chloro-5-nitrobenzanilide 91-97 peroxisome proliferator activated receptor gamma Mus musculus 49-58 27103568-10 2016 Moreover, D-allose induced up-regulation of peroxisome proliferator-activated receptor gamma (PPARgamma), and down-regulation of TNF-alpha and NF-kappaB after MCAO/Rep, which were abolished by utilization of GW9662. 2-chloro-5-nitrobenzanilide 208-214 peroxisome proliferator activated receptor gamma Mus musculus 44-92 27103568-10 2016 Moreover, D-allose induced up-regulation of peroxisome proliferator-activated receptor gamma (PPARgamma), and down-regulation of TNF-alpha and NF-kappaB after MCAO/Rep, which were abolished by utilization of GW9662. 2-chloro-5-nitrobenzanilide 208-214 peroxisome proliferator activated receptor gamma Mus musculus 94-103 27679746-8 2016 PD123319 and GW-9662 were used to selectively block the AT2R and peroxisome proliferator-activated receptor-gamma (PPAR-gamma), respectively. 2-chloro-5-nitrobenzanilide 13-20 peroxisome proliferator activated receptor gamma Mus musculus 65-113 27679746-8 2016 PD123319 and GW-9662 were used to selectively block the AT2R and peroxisome proliferator-activated receptor-gamma (PPAR-gamma), respectively. 2-chloro-5-nitrobenzanilide 13-20 peroxisome proliferator activated receptor gamma Mus musculus 115-125 27171144-7 2016 Furthermore, Sirt1 also deacetylated p53 and then increased the binding of p53 to Bax, resulting in increased cytosolic cytochrome C. The effect of PPARgamma inactivation by PFOS was validated using the PPARgamma antagonist GW9662, whereas the adverse effects of PFOS were prevented by PPARgamma overexpression and activators, rosiglitozone and L-carnitine, in RTCs. 2-chloro-5-nitrobenzanilide 224-230 peroxisome proliferator activated receptor gamma Mus musculus 148-157 27544994-10 2016 PPAR-gamma antagonist GW9662 reversed the effect of 15 d-PGJ2 (mRNA,1.48+-0.06,P=0.016;protein,1.28). 2-chloro-5-nitrobenzanilide 22-28 peroxisome proliferator activated receptor gamma Mus musculus 0-10 27054331-8 2016 We demonstrated that the upregulation of Ccr2 expression by Per1 deletion could be reversed by the synthetic peroxisome proliferator-activated receptor gamma (PPAR-gamma) antagonist GW9662. 2-chloro-5-nitrobenzanilide 182-188 peroxisome proliferator activated receptor gamma Mus musculus 109-157 27493874-12 2016 Treatment with all-trans retinoic acid prevented the formation of intramuscular fat; however, treatment with GW9662, a PPARgamma antagonist, increased the fibrotic change in muscle. 2-chloro-5-nitrobenzanilide 109-115 peroxisome proliferator activated receptor gamma Mus musculus 119-128 27054331-8 2016 We demonstrated that the upregulation of Ccr2 expression by Per1 deletion could be reversed by the synthetic peroxisome proliferator-activated receptor gamma (PPAR-gamma) antagonist GW9662. 2-chloro-5-nitrobenzanilide 182-188 peroxisome proliferator activated receptor gamma Mus musculus 159-169 26618986-7 2016 Polymorphonuclear leukocytes (PMN) incubated with LPS or Escherichia coli and rosiglitazone increased peritoneal neutrophil extracellular trap (NET)-mediated bacterial killing, an effect reversed by the PPARgamma antagonist (GW 9662) treatment. 2-chloro-5-nitrobenzanilide 225-232 peroxisome proliferator activated receptor gamma Mus musculus 203-212 26921464-5 2016 Conversely, treatment with a PPARgamma antagonist (GW9662) reversed these outcomes. 2-chloro-5-nitrobenzanilide 51-57 peroxisome proliferator activated receptor gamma Mus musculus 29-38 26750154-13 2016 Also GW9662, a selective PPAR-gamma antagonist, almost completely prevented the madecassoside-induced increased expression of HGF and amelioration of PF. 2-chloro-5-nitrobenzanilide 5-11 peroxisome proliferator activated receptor gamma Mus musculus 25-35 26660152-5 2016 GW9662 (10 micromol/L), an antagonist of PPARgamma, reversed the effects of farnesol on cellular lipid content, suggesting that PPARgamma signaling pathway may mediate the farnesol effect. 2-chloro-5-nitrobenzanilide 0-6 peroxisome proliferator activated receptor gamma Mus musculus 41-50 26857685-10 2016 Tamoxifen also reduced EtOH consumption in male mice and this action was inhibited by GW9662, but not MK886, suggesting that it acts by activation of PPARgamma. 2-chloro-5-nitrobenzanilide 86-92 peroxisome proliferator activated receptor gamma Mus musculus 150-159 26660152-5 2016 GW9662 (10 micromol/L), an antagonist of PPARgamma, reversed the effects of farnesol on cellular lipid content, suggesting that PPARgamma signaling pathway may mediate the farnesol effect. 2-chloro-5-nitrobenzanilide 0-6 peroxisome proliferator activated receptor gamma Mus musculus 128-137 26099526-4 2015 Some mice were given an inhibitor (GW9662) of peroxisome proliferator-activated receptor gamma (PPARG). 2-chloro-5-nitrobenzanilide 35-41 peroxisome proliferator activated receptor gamma Mus musculus 96-101 26893620-4 2016 Therefore, the present study aimed to investigate the effects of the PPAR agonist rosiglitazone and the specific PPARgamma antagonist GW9662 on tumor metastasis following hepatic I/R. 2-chloro-5-nitrobenzanilide 134-140 peroxisome proliferator activated receptor gamma Mus musculus 113-122 26597823-9 2016 Interference with PPARgamma activity either by treatment with a PPARgamma inhibitor, GW9662, or by expressing P467L PPARgamma markedly suppressed TIMP-4 in primary smooth muscle cells. 2-chloro-5-nitrobenzanilide 85-91 peroxisome proliferator activated receptor gamma Mus musculus 18-27 26954392-10 2016 We determined whether GW9662, a specific PPARgamma inhibitor, could abolish the anti-inflammatory effect of DHA and celecoxib. 2-chloro-5-nitrobenzanilide 22-28 peroxisome proliferator activated receptor gamma Mus musculus 41-50 26954392-11 2016 GW9662 has abolished the DHA and celecoxib induced PPARgamma activation, but did not alter the NF-kappaB mediated anti-inflammatory effects induced by celecoxib and DHA. 2-chloro-5-nitrobenzanilide 0-6 peroxisome proliferator activated receptor gamma Mus musculus 51-60 26053972-12 2016 The PPARgamma antagonist GW9662 inhibited adipogenesis. 2-chloro-5-nitrobenzanilide 25-31 peroxisome proliferator activated receptor gamma Mus musculus 4-13 26099526-4 2015 Some mice were given an inhibitor (GW9662) of peroxisome proliferator-activated receptor gamma (PPARG). 2-chloro-5-nitrobenzanilide 35-41 peroxisome proliferator activated receptor gamma Mus musculus 46-94 26781175-5 2016 The PPARgamma agonist, pioglitazone, and PPARgamma inhibitor, GW9662, were administered to the mice, respectively. 2-chloro-5-nitrobenzanilide 62-68 peroxisome proliferator activated receptor gamma Mus musculus 41-50 26647854-9 2016 The inhibitory effect of L-carnitine on the increased expression level of nuclear factor (NF)-kappaB p65 in the peripheral blood mononuclear cells was markedly weakened by GW9662, a selective inhibitor of PPAR-gamma. 2-chloro-5-nitrobenzanilide 172-178 peroxisome proliferator activated receptor gamma Mus musculus 205-215 26590117-9 2015 Inhibition of PPAR-gamma by GW9662 reduced the anti-inflammatory effects of melatonin. 2-chloro-5-nitrobenzanilide 28-34 peroxisome proliferator activated receptor gamma Mus musculus 14-24 26031185-7 2015 GW9662 treatment reversed the expression of PPAR-gamma without altering the expression of steroidogenic enzymes and corticosterone secretion in the colon, while metyrapone treatment blocked glucocorticoid secretion and abrogated the increase in PPAR-gamma expression in the colon. 2-chloro-5-nitrobenzanilide 0-6 peroxisome proliferator activated receptor gamma Mus musculus 44-54 26031185-7 2015 GW9662 treatment reversed the expression of PPAR-gamma without altering the expression of steroidogenic enzymes and corticosterone secretion in the colon, while metyrapone treatment blocked glucocorticoid secretion and abrogated the increase in PPAR-gamma expression in the colon. 2-chloro-5-nitrobenzanilide 0-6 peroxisome proliferator activated receptor gamma Mus musculus 245-255 25920446-6 2015 In contrast, adding PPAR-gamma antagonist, GW9662, to podocytes largely prevented the inhibition of collagen IV expression from Pio treatment. 2-chloro-5-nitrobenzanilide 43-49 peroxisome proliferator activated receptor gamma Mus musculus 20-30 26035689-9 2015 Furthermore, the PPARgamma, antagonist GW9662, attenuated the promoting effects of OCSCs on the M2 polarization of macrophages. 2-chloro-5-nitrobenzanilide 39-45 peroxisome proliferator activated receptor gamma Mus musculus 17-26 25586556-6 2015 Coadministration of the PPARgamma antagonist, GW9662, reversed the enhanced efferocytosis, and the reduced proinflammatory cytokine expression, neutrophil recruitment, myeloperoxidase activity, hydroxyproline contents, and fibrosis markers, including type 1 collagen alpha2, fibronectin and alpha-smooth muscle actin (alpha-SMA), in the lung by apoptotic cell instillation. 2-chloro-5-nitrobenzanilide 46-52 peroxisome proliferator activated receptor gamma Mus musculus 24-33 26322101-4 2015 MATERIAL AND METHODS: Female ApoE(-/-)/AT1R(-/-) mice were fedwith a high-fat and cholesterol-rich diet and received continuous treatment with the selective PPARgamma antagonist GW9662 or vehicle at a rate of 700 ng/kg/min for 4 weeks using subcutaneously implanted osmotic mini-pumps. 2-chloro-5-nitrobenzanilide 178-184 peroxisome proliferator activated receptor gamma Mus musculus 157-166 25714973-9 2015 Furthermore, our data showed that the increased level of peroxisome proliferator-activated receptor gamma (PPARgamma) and the up-regulation of insulin degrading enzyme induced by NTR1 were inhibited by administration of GW9662 (a PPARgamma antagonist), indicating that the effect of NTR1 was mediated, at least in part, by PPARgamma. 2-chloro-5-nitrobenzanilide 220-226 peroxisome proliferator activated receptor gamma Mus musculus 57-105 26061913-8 2015 These effects of pioglitazone were reversed by GW9662, a PPARgamma antagonist, indicating that PPARgamma is involved in this process. 2-chloro-5-nitrobenzanilide 47-53 peroxisome proliferator activated receptor gamma Mus musculus 57-66 26061913-8 2015 These effects of pioglitazone were reversed by GW9662, a PPARgamma antagonist, indicating that PPARgamma is involved in this process. 2-chloro-5-nitrobenzanilide 47-53 peroxisome proliferator activated receptor gamma Mus musculus 95-104 25931465-5 2015 PPARgamma antagonist (GW9662) abolished the protective effect of pioglitazone. 2-chloro-5-nitrobenzanilide 22-28 peroxisome proliferator activated receptor gamma Mus musculus 0-9 25701789-10 2015 However, all of these beneficial effects induced by voluntary exercise were abolished by GW9662, which inhibited expression and activity of PPAR-gamma. 2-chloro-5-nitrobenzanilide 89-95 peroxisome proliferator activated receptor gamma Mus musculus 140-150 25618409-7 2015 The effects seen with cardiomyocyte-specific expression of CYP2J2 were partially blocked by treatment with PPAR-gamma antagonist GW9662. 2-chloro-5-nitrobenzanilide 129-135 peroxisome proliferator activated receptor gamma Mus musculus 107-117 25281205-9 2015 Furthermore, we found that citral activated PPAR-gamma and the anti-inflammatory effects of citral can be reversed by PPAR-gamma antagonist GW9662. 2-chloro-5-nitrobenzanilide 140-146 peroxisome proliferator activated receptor gamma Mus musculus 118-128 25497712-11 2015 Moreover, PAB inhibited the activation of p38MAPK, ATF-2, MK2, and HSP27 significantly, as well as the production of TNF-alpha, which was reversed by GW9662, a specific antagonist for PPARgamma. 2-chloro-5-nitrobenzanilide 150-156 peroxisome proliferator activated receptor gamma Mus musculus 184-193 25714973-9 2015 Furthermore, our data showed that the increased level of peroxisome proliferator-activated receptor gamma (PPARgamma) and the up-regulation of insulin degrading enzyme induced by NTR1 were inhibited by administration of GW9662 (a PPARgamma antagonist), indicating that the effect of NTR1 was mediated, at least in part, by PPARgamma. 2-chloro-5-nitrobenzanilide 220-226 peroxisome proliferator activated receptor gamma Mus musculus 107-116 25714973-9 2015 Furthermore, our data showed that the increased level of peroxisome proliferator-activated receptor gamma (PPARgamma) and the up-regulation of insulin degrading enzyme induced by NTR1 were inhibited by administration of GW9662 (a PPARgamma antagonist), indicating that the effect of NTR1 was mediated, at least in part, by PPARgamma. 2-chloro-5-nitrobenzanilide 220-226 peroxisome proliferator activated receptor gamma Mus musculus 230-239 25714973-9 2015 Furthermore, our data showed that the increased level of peroxisome proliferator-activated receptor gamma (PPARgamma) and the up-regulation of insulin degrading enzyme induced by NTR1 were inhibited by administration of GW9662 (a PPARgamma antagonist), indicating that the effect of NTR1 was mediated, at least in part, by PPARgamma. 2-chloro-5-nitrobenzanilide 220-226 peroxisome proliferator activated receptor gamma Mus musculus 230-239 25044948-8 2014 Pretreatment with PPARgamma inhibitor (GW9662) abolished the inhibitory effect of DHA (100 muM) on LA-induced IkappaB degradation, p65 translocation, and MCP-1 expression in ARPE-19 cells (p < 0.05), as well as tube formation in RF6A. 2-chloro-5-nitrobenzanilide 39-45 peroxisome proliferator activated receptor gamma Mus musculus 18-27 25249228-11 2015 GW9662 attenuated the telmisartan-induced increase in PPARgamma expression, the LC3-II/LC3-I ratio and p-AMPK expression and the telmisartan-induced decrease in p-mTOR expression. 2-chloro-5-nitrobenzanilide 0-6 peroxisome proliferator activated receptor gamma Mus musculus 54-63 25048682-7 2014 However, pretreatment with GW-9662 (5 mg kg(-1) , bid), a selective PPARgamma antagonist, completely abolished this effect. 2-chloro-5-nitrobenzanilide 27-34 peroxisome proliferator activated receptor gamma Mus musculus 68-77 25288222-10 2014 More importantly, these effects were significantly attenuated when mice were pre-injected with the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) antagonist, GW9662. 2-chloro-5-nitrobenzanilide 173-179 peroxisome proliferator activated receptor gamma Mus musculus 99-147 25288222-10 2014 More importantly, these effects were significantly attenuated when mice were pre-injected with the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) antagonist, GW9662. 2-chloro-5-nitrobenzanilide 173-179 peroxisome proliferator activated receptor gamma Mus musculus 149-159 25425470-8 2015 All pioglitazone-studied effects were antagonized by GW9662, a selective PPARgamma antagonist. 2-chloro-5-nitrobenzanilide 53-59 peroxisome proliferator activated receptor gamma Mus musculus 73-82 24914897-7 2014 The stimulating effect of sesamin on cholesterol efflux was substantially inhibited by the co-treatment with GW9662, a potent inhibitor of PPARgamma. 2-chloro-5-nitrobenzanilide 109-115 peroxisome proliferator activated receptor gamma Mus musculus 139-148 24975659-7 2014 Moreover, the PPARgamma antagonist GW9662 and RXR antagonist 6-[N-4-(trifluoromethyl)-benzenesulfonyl-N-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-amino] nicotinic acid (NS-4TF) had no effect on the anti-inflammatory effect of the GR agonist dexamethasone. 2-chloro-5-nitrobenzanilide 35-41 peroxisome proliferator activated receptor gamma Mus musculus 14-23 24874440-8 2014 Furthermore, emodin could activate PPAR-gamma and the anti-inflammatory effects of emodin can be reversed by GW9662, a specific antagonist for PPAR-gamma. 2-chloro-5-nitrobenzanilide 109-115 peroxisome proliferator activated receptor gamma Mus musculus 35-45 24874440-8 2014 Furthermore, emodin could activate PPAR-gamma and the anti-inflammatory effects of emodin can be reversed by GW9662, a specific antagonist for PPAR-gamma. 2-chloro-5-nitrobenzanilide 109-115 peroxisome proliferator activated receptor gamma Mus musculus 143-153 24424383-4 2014 In contrast, exposure to GW9662 (PPARgamma antagonist) exacerbated Tat-induced disruption of the BBB integrity. 2-chloro-5-nitrobenzanilide 25-31 peroxisome proliferator activated receptor gamma Mus musculus 33-42 24132472-9 2014 The PPAR-gamma antagonist GW9662 prevented the TBBPA-induced decrease in PPAR-gamma protein level, but it potentiated TBBPA-induced apoptotic and neurotoxic effects, which suggest that the mechanism of TBBPA action in neuronal cells is not only PPAR-gamma-dependent. 2-chloro-5-nitrobenzanilide 26-32 peroxisome proliferator activated receptor gamma Mus musculus 4-14 24132472-9 2014 The PPAR-gamma antagonist GW9662 prevented the TBBPA-induced decrease in PPAR-gamma protein level, but it potentiated TBBPA-induced apoptotic and neurotoxic effects, which suggest that the mechanism of TBBPA action in neuronal cells is not only PPAR-gamma-dependent. 2-chloro-5-nitrobenzanilide 26-32 peroxisome proliferator activated receptor gamma Mus musculus 73-83 24132472-9 2014 The PPAR-gamma antagonist GW9662 prevented the TBBPA-induced decrease in PPAR-gamma protein level, but it potentiated TBBPA-induced apoptotic and neurotoxic effects, which suggest that the mechanism of TBBPA action in neuronal cells is not only PPAR-gamma-dependent. 2-chloro-5-nitrobenzanilide 26-32 peroxisome proliferator activated receptor gamma Mus musculus 73-83 24708771-11 2014 Further, the effects of RvD1 and IL-4 on Arg1 and Ym1 were blocked by the application of leflunomide (a STAT6 inhibitor) or GW9662 (a PPARgamma antagonist). 2-chloro-5-nitrobenzanilide 124-130 peroxisome proliferator activated receptor gamma Mus musculus 134-143 22696146-5 2012 We found that treatment of mice with GW9662, a PPARgamma antagonist, prior to i.n. 2-chloro-5-nitrobenzanilide 37-43 peroxisome proliferator activated receptor gamma Mus musculus 47-56 24466034-8 2014 GW9662, a selective peroxisome proliferator-activated receptor-gamma antagonist, enhanced the increase in NF-kappaB activity and WDR35 protein expression in bupivacaine-treated Neuro2a cells. 2-chloro-5-nitrobenzanilide 0-6 peroxisome proliferator activated receptor gamma Mus musculus 20-68 25171128-6 2014 The use of the CB2 antagonist AM630 or the PPARgamma antagonist GW9662 significantly reversed the protective effects of beta-caryophyllene on APP/PS1 mice. 2-chloro-5-nitrobenzanilide 64-70 peroxisome proliferator activated receptor gamma Mus musculus 43-52 23790735-9 2013 Treatment with a PPARgamma antagonist GW9662 reversed some of the effects of irbesartan. 2-chloro-5-nitrobenzanilide 38-44 peroxisome proliferator activated receptor gamma Mus musculus 17-26 21153483-5 2013 The protective effects of the TZDs on NIT-1 cells disappeared when PPARgamma was blocked with PPARgamma-siRNA interference or treatment with GW9662, the PPARgamma antagonist. 2-chloro-5-nitrobenzanilide 141-147 peroxisome proliferator activated receptor gamma Mus musculus 67-76 23374104-10 2013 Treatment of diabetic ApoE-/- and ApoE-/-/AT1R-/--mice with the selective PPARgamma antagonist GW9662 omitted the atheroprotective effects of AT1R deficiency or AT1 antagonism. 2-chloro-5-nitrobenzanilide 95-101 peroxisome proliferator activated receptor gamma Mus musculus 74-83 23001870-0 2013 PPARgamma antagonist GW9662 induces functional estrogen receptor in mouse mammary organ culture: potential translational significance. 2-chloro-5-nitrobenzanilide 21-27 peroxisome proliferator activated receptor gamma Mus musculus 0-9 23199346-12 2012 The PPARgamma inhibitor GW9662 partially reversed RvD1-induced suppression of IkappaBalpha degradation and p65 nuclear translocation. 2-chloro-5-nitrobenzanilide 24-30 peroxisome proliferator activated receptor gamma Mus musculus 4-13 22594400-7 2012 This increase in PPARgamma expression is blocked by the PPARgamma antagonist, GW9662, indicating a transcriptional feedback loop involving PPARgamma activation of itself. 2-chloro-5-nitrobenzanilide 78-84 peroxisome proliferator activated receptor gamma Mus musculus 17-26 22594400-7 2012 This increase in PPARgamma expression is blocked by the PPARgamma antagonist, GW9662, indicating a transcriptional feedback loop involving PPARgamma activation of itself. 2-chloro-5-nitrobenzanilide 78-84 peroxisome proliferator activated receptor gamma Mus musculus 56-65 22594400-7 2012 This increase in PPARgamma expression is blocked by the PPARgamma antagonist, GW9662, indicating a transcriptional feedback loop involving PPARgamma activation of itself. 2-chloro-5-nitrobenzanilide 78-84 peroxisome proliferator activated receptor gamma Mus musculus 56-65 22594400-8 2012 Adiponectin causes a significant increase in insulin content and secretion and this occurs also via PPARgamma activation due to the inhibitory effect of GW9662. 2-chloro-5-nitrobenzanilide 153-159 peroxisome proliferator activated receptor gamma Mus musculus 100-109 24338020-7 2014 PPARgamma antagonists (bisphenol A diglycidyl ether or GW9662) blunted the effects of rosiglitazone on PHD regulation. 2-chloro-5-nitrobenzanilide 55-61 peroxisome proliferator activated receptor gamma Mus musculus 0-9 24163073-7 2014 The role of PPARgamma was further specified by using the selective PPARgamma antagonist GW9662. 2-chloro-5-nitrobenzanilide 88-94 peroxisome proliferator activated receptor gamma Mus musculus 67-76 23647130-7 2013 GW9662, a PPAR-gamma antagonist, was administered 30 min prior to first pretreatment with losartan. 2-chloro-5-nitrobenzanilide 0-6 peroxisome proliferator activated receptor gamma Mus musculus 10-20 23673903-5 2013 In addition, inhibitions of inflammatory factor production, serum dyslipidemia, and hepatic fatty acid accumulation by MS and pioglitazone were attenuated by GW9662 (PPARgamma antagonist). 2-chloro-5-nitrobenzanilide 158-164 peroxisome proliferator activated receptor gamma Mus musculus 166-175 23608606-7 2013 Importantly, anti-hepatocyte growth factor (HGF) neutralizing antibody and a PPARgamma antagonist (GW9662) attenuated these organ-protective effects of irbesartan. 2-chloro-5-nitrobenzanilide 99-105 peroxisome proliferator activated receptor gamma Mus musculus 77-86 23628590-2 2013 We demonstrated that in the presence of LIF, the activation of PPARgamma by Rosiglitazone led to an increased proliferation of mESCs whereas PPARgamma antagonist (GW9662) reversed this effect. 2-chloro-5-nitrobenzanilide 163-169 peroxisome proliferator activated receptor gamma Mus musculus 141-150 23178929-8 2013 Both the transactivation and binding activity of PPARgamma by ionomycin can be blocked by PPARgamma specific antagonist GW9662. 2-chloro-5-nitrobenzanilide 120-126 peroxisome proliferator activated receptor gamma Mus musculus 49-58 23178929-8 2013 Both the transactivation and binding activity of PPARgamma by ionomycin can be blocked by PPARgamma specific antagonist GW9662. 2-chloro-5-nitrobenzanilide 120-126 peroxisome proliferator activated receptor gamma Mus musculus 90-99 22917565-8 2013 Moreover GW9662, a specific PPARgamma antagonist, revealed the participation of other signaling pathways since, in GW9662 presence, 15dPJG2 had a partial effect on the inhibition of inflammatory parameters in the acute model of infection. 2-chloro-5-nitrobenzanilide 9-15 peroxisome proliferator activated receptor gamma Mus musculus 28-37 23220503-7 2013 Moreover, in A549-xenografted nude mice, cannabidiol caused upregulation of COX-2 and PPAR-gamma in tumor tissue and tumor regression that was reversible by GW9662. 2-chloro-5-nitrobenzanilide 157-163 peroxisome proliferator activated receptor gamma Mus musculus 86-96 23085268-5 2012 The inhibitory effect of ACS14 on CX3CR1 expression was abolished by pretreatment with GW9662, a selective peroxisome proliferator-activated receptor (PPAR)-gamma antagonist, suggesting that suppression of macrophage CX3CR1 expression by ACS14 is PPAR-gamma dependent. 2-chloro-5-nitrobenzanilide 87-93 peroxisome proliferator activated receptor gamma Mus musculus 107-162 23085268-5 2012 The inhibitory effect of ACS14 on CX3CR1 expression was abolished by pretreatment with GW9662, a selective peroxisome proliferator-activated receptor (PPAR)-gamma antagonist, suggesting that suppression of macrophage CX3CR1 expression by ACS14 is PPAR-gamma dependent. 2-chloro-5-nitrobenzanilide 87-93 peroxisome proliferator activated receptor gamma Mus musculus 247-257 23042820-8 2012 Eicosapentaenoic acid blocked rosiglitazone (a PPARgamma agonist)-mediated EL activation and GW9662 (a PPARgamma antagonist)-blocked palmitic acid-mediated EL stimulation. 2-chloro-5-nitrobenzanilide 93-99 peroxisome proliferator activated receptor gamma Mus musculus 103-112 22879581-5 2012 The therapeutic effects of pioglitazone-incorporated NP were diminished by the peroxisome proliferator activated receptor-gamma antagonist GW9662 and were not observed in endothelial NO synthase-deficient mice. 2-chloro-5-nitrobenzanilide 139-145 peroxisome proliferator activated receptor gamma Mus musculus 79-127 22467332-11 2012 Increased apoptosis and inflammation was also observed after treatment with the PPARgamma antagonist GW9662. 2-chloro-5-nitrobenzanilide 101-107 peroxisome proliferator activated receptor gamma Mus musculus 80-89 22634137-8 2012 Inhibition of PPARgamma by GW9662, a specific PPARgamma-antagonist reduced 17ss-estradiol mediated vascular effects (OVX/E2+GW9662). 2-chloro-5-nitrobenzanilide 27-33 peroxisome proliferator activated receptor gamma Mus musculus 14-23 22634137-8 2012 Inhibition of PPARgamma by GW9662, a specific PPARgamma-antagonist reduced 17ss-estradiol mediated vascular effects (OVX/E2+GW9662). 2-chloro-5-nitrobenzanilide 124-130 peroxisome proliferator activated receptor gamma Mus musculus 46-55 22634137-8 2012 Inhibition of PPARgamma by GW9662, a specific PPARgamma-antagonist reduced 17ss-estradiol mediated vascular effects (OVX/E2+GW9662). 2-chloro-5-nitrobenzanilide 27-33 peroxisome proliferator activated receptor gamma Mus musculus 46-55 22634137-8 2012 Inhibition of PPARgamma by GW9662, a specific PPARgamma-antagonist reduced 17ss-estradiol mediated vascular effects (OVX/E2+GW9662). 2-chloro-5-nitrobenzanilide 124-130 peroxisome proliferator activated receptor gamma Mus musculus 14-23 22417924-3 2012 This study explored the impact of the PPARgamma agonist rosiglitazone and the PPARgamma antagonist GW9662 in the MPP(+)/MPTP (1-methyl-4-phenylpyridinium/1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) model of Parkinson"s disease, focussing on oxidative stress mechanisms. 2-chloro-5-nitrobenzanilide 99-105 peroxisome proliferator activated receptor gamma Mus musculus 78-87 22221312-6 2012 GW-9662, a PPARgamma antagonist, inhibited the stimulating effect of TZDs on SK-1 mRNA and activity levels and intracellular S1P concentrations. 2-chloro-5-nitrobenzanilide 0-7 peroxisome proliferator activated receptor gamma Mus musculus 11-20 22417924-7 2012 The importance of PPARgamma in protecting against MPTP toxicity was confirmed by treating C57BL6 mice with GW9662. 2-chloro-5-nitrobenzanilide 107-113 peroxisome proliferator activated receptor gamma Mus musculus 18-27 22538444-7 2012 Tumors from GW9662-treated animals exhibited reduced expression of a metabolic gene profile indicative of PPARgamma inhibition, including PPARgamma itself. 2-chloro-5-nitrobenzanilide 12-18 peroxisome proliferator activated receptor gamma Mus musculus 106-115 22454480-5 2012 Cotreatment with GW9662, a peroxisome proliferator-activated receptor-gamma antagonist, interfered with these protective effects of telmisartan against cognitive function. 2-chloro-5-nitrobenzanilide 17-23 peroxisome proliferator activated receptor gamma Mus musculus 27-75 22037925-4 2012 pre-treatment of mice with LY294002 (10 nmol/site, a PI3K inhibitor) or GW-9662 (1 microg/site, a PPARgamma antagonist) prevented the antidepressant-like effect of folic acid (50 mg/kg, p.o.) 2-chloro-5-nitrobenzanilide 72-79 peroxisome proliferator activated receptor gamma Mus musculus 98-107 20950829-6 2012 In mixed lymphocytes reaction (MLR), incubation with EPA significantly inhibited the proliferation of IL-17(+) T cells and promoted the proliferation of Tregs, while PPARgamma antagonists GW9662 could reverse the results. 2-chloro-5-nitrobenzanilide 188-194 peroxisome proliferator activated receptor gamma Mus musculus 166-175 22538444-7 2012 Tumors from GW9662-treated animals exhibited reduced expression of a metabolic gene profile indicative of PPARgamma inhibition, including PPARgamma itself. 2-chloro-5-nitrobenzanilide 12-18 peroxisome proliferator activated receptor gamma Mus musculus 138-147 22252391-6 2012 Importantly, the prevention of renal atrophy and fibrosis by telmisartan was significantly attenuated by GW9662, a PPARgamma antagonist. 2-chloro-5-nitrobenzanilide 105-111 peroxisome proliferator activated receptor gamma Mus musculus 115-124 22099177-5 2012 Our results indicated that PPARgamma inactivation via treatment with GW9662 during NPs formation, reduced expression of neural precursor and neural (neuronal and astrocytes) markers. 2-chloro-5-nitrobenzanilide 69-75 peroxisome proliferator activated receptor gamma Mus musculus 27-36 21946955-6 2012 Inhibition of PPARgamma activity by its antagonist GW9662 significantly reversed the anti-inflammatory effect of biochanin A but not genistein, which demonstrated the dependency of biochanin A and the independency of genistein on PPARgamma in their anti-inflammatory actions. 2-chloro-5-nitrobenzanilide 51-57 peroxisome proliferator activated receptor gamma Mus musculus 14-23 23316104-5 2012 Ablation of PPARgamma with small interfering RNA or GW9662-mediated inhibition of PPARgamma abolished the effect of rosiglitazone on HMGB1 release. 2-chloro-5-nitrobenzanilide 52-58 peroxisome proliferator activated receptor gamma Mus musculus 82-91 21946955-6 2012 Inhibition of PPARgamma activity by its antagonist GW9662 significantly reversed the anti-inflammatory effect of biochanin A but not genistein, which demonstrated the dependency of biochanin A and the independency of genistein on PPARgamma in their anti-inflammatory actions. 2-chloro-5-nitrobenzanilide 51-57 peroxisome proliferator activated receptor gamma Mus musculus 230-239 21946955-7 2012 Meanwhile, the PPARgamma-dependency of biochanin A was further confirmed by the result that the suppression of LPS-induced NF-kappaB activation by biochanin A was reversed following GW9662 co-treatment. 2-chloro-5-nitrobenzanilide 182-188 peroxisome proliferator activated receptor gamma Mus musculus 15-24 23155382-7 2012 C21 treatment increased serum adiponectin concentration and decreased TNF-alpha concentration; however, these effects were attenuated by PPARgamma blockade by co-treatment with GW9662. 2-chloro-5-nitrobenzanilide 177-183 peroxisome proliferator activated receptor gamma Mus musculus 137-146 21907585-3 2012 METHODS: Four analogs of GW9662, a PPARgamma antagonist, with different fluorine-containing substituents at the para-position of the aniline ring were synthesized and evaluated using two different receptor binding assays for measuring PPARgamma affinity. 2-chloro-5-nitrobenzanilide 25-31 peroxisome proliferator activated receptor gamma Mus musculus 35-44 21907585-3 2012 METHODS: Four analogs of GW9662, a PPARgamma antagonist, with different fluorine-containing substituents at the para-position of the aniline ring were synthesized and evaluated using two different receptor binding assays for measuring PPARgamma affinity. 2-chloro-5-nitrobenzanilide 25-31 peroxisome proliferator activated receptor gamma Mus musculus 235-244 21804572-10 2011 In BV-2 cells subjected to hypoxia, T33 (0.5 mumol/L) reduced TNF-alpha, COX-2, and p-P38 production, which was antagonized by pre-administration of the specific PPARgamma antagonist GW9662 (30 mumol/L). 2-chloro-5-nitrobenzanilide 183-189 peroxisome proliferator activated receptor gamma Mus musculus 162-171 21397693-4 2011 Here we show that TBT can activate the RXR-PPARgamma heterodimer even in the presence of the PPARgamma antagonist GW9662. 2-chloro-5-nitrobenzanilide 114-120 peroxisome proliferator activated receptor gamma Mus musculus 43-52 21397693-4 2011 Here we show that TBT can activate the RXR-PPARgamma heterodimer even in the presence of the PPARgamma antagonist GW9662. 2-chloro-5-nitrobenzanilide 114-120 peroxisome proliferator activated receptor gamma Mus musculus 93-102 22199113-4 2011 GW9662 (0.3 mg/kg), a specific peroxisome proliferator-activated receptor gamma (PPARgamma) antagonist, was intravenously injected along with curcumin. 2-chloro-5-nitrobenzanilide 0-6 peroxisome proliferator activated receptor gamma Mus musculus 31-79 22199113-4 2011 GW9662 (0.3 mg/kg), a specific peroxisome proliferator-activated receptor gamma (PPARgamma) antagonist, was intravenously injected along with curcumin. 2-chloro-5-nitrobenzanilide 0-6 peroxisome proliferator activated receptor gamma Mus musculus 81-90 21856391-9 2011 Administration of the PPARgamma agonist (troglitazone) enhanced DEHP-induced Trim17 protein expression and this enhancement could be reversed by the PPARgamma antagonist (GW9662). 2-chloro-5-nitrobenzanilide 171-177 peroxisome proliferator activated receptor gamma Mus musculus 22-31 21856391-9 2011 Administration of the PPARgamma agonist (troglitazone) enhanced DEHP-induced Trim17 protein expression and this enhancement could be reversed by the PPARgamma antagonist (GW9662). 2-chloro-5-nitrobenzanilide 171-177 peroxisome proliferator activated receptor gamma Mus musculus 149-158 21777645-7 2011 Moreover, we found that MS may act a PPAR-gamma agonist to improve insulin sensitivity, and this issue was further confirmed by PPAR-gamma antagonist (GW9662). 2-chloro-5-nitrobenzanilide 151-157 peroxisome proliferator activated receptor gamma Mus musculus 128-138 21666107-10 2011 Intriguingly, pretreatment with the selective PPAR-gamma inhibitor GW-9662 (1 mug/g iv) 10 min before reperfusion significantly attenuated these beneficial effects of RGZ on the ischemic heart. 2-chloro-5-nitrobenzanilide 67-74 peroxisome proliferator activated receptor gamma Mus musculus 46-56 20471230-7 2011 Furthermore, GW9662 (the inhibitor of PPAR-gamma) significantly reversed these beneficial effects of AS in septic mice. 2-chloro-5-nitrobenzanilide 13-19 peroxisome proliferator activated receptor gamma Mus musculus 38-48 21734632-5 2011 The PPARgamma pathway plays a important roles in this effect of PMQ because blockade of PPARgamma by GW9662 eliminates the PMQ-induced up-regulation of adiponectin expression. 2-chloro-5-nitrobenzanilide 101-107 peroxisome proliferator activated receptor gamma Mus musculus 4-13 21544063-6 2011 This renoprotective effect was reversed by concomitant administration of the PPARgamma antagonist GW9662 throughout the EGCG pretreatment period. 2-chloro-5-nitrobenzanilide 98-104 peroxisome proliferator activated receptor gamma Mus musculus 77-86 21111596-9 2011 To understand the functional implication of the physical association of PPARgamma with NF-kappaB, we determined whether the specific PPARgamma inhibitor, GW9662 could abolish the anti-inflammatory effect of n-3 PUFA Inhibiting PPARgamma did not impede the NF-kappaB-mediated anti-inflammatory cytokine profile induced by EPA and DHA alone. 2-chloro-5-nitrobenzanilide 154-160 peroxisome proliferator activated receptor gamma Mus musculus 72-81 21111596-9 2011 To understand the functional implication of the physical association of PPARgamma with NF-kappaB, we determined whether the specific PPARgamma inhibitor, GW9662 could abolish the anti-inflammatory effect of n-3 PUFA Inhibiting PPARgamma did not impede the NF-kappaB-mediated anti-inflammatory cytokine profile induced by EPA and DHA alone. 2-chloro-5-nitrobenzanilide 154-160 peroxisome proliferator activated receptor gamma Mus musculus 133-142 21111596-9 2011 To understand the functional implication of the physical association of PPARgamma with NF-kappaB, we determined whether the specific PPARgamma inhibitor, GW9662 could abolish the anti-inflammatory effect of n-3 PUFA Inhibiting PPARgamma did not impede the NF-kappaB-mediated anti-inflammatory cytokine profile induced by EPA and DHA alone. 2-chloro-5-nitrobenzanilide 154-160 peroxisome proliferator activated receptor gamma Mus musculus 133-142 21734632-5 2011 The PPARgamma pathway plays a important roles in this effect of PMQ because blockade of PPARgamma by GW9662 eliminates the PMQ-induced up-regulation of adiponectin expression. 2-chloro-5-nitrobenzanilide 101-107 peroxisome proliferator activated receptor gamma Mus musculus 88-97 21471100-6 2011 MEASUREMENTS AND MAIN RESULTS: PPARgamma inhibition in T cells with either the PPARgamma antagonist GW9662 or a newly generated T cell-specific PPARgamma knockout (Tc-PPARgamma(-/-)) mice provided a survival advantage during polymicrobial sepsis in mice, which correlated with abrogated T-cell depletion in both in vivo models. 2-chloro-5-nitrobenzanilide 100-106 peroxisome proliferator activated receptor gamma Mus musculus 31-40 21734368-6 2011 HK-2 cells were maintained under defined in vitro conditions, treated with either rosiglitazone and/or the PPAR-gamma antagonist GW9662, and then stimulated with LPS. 2-chloro-5-nitrobenzanilide 129-135 peroxisome proliferator activated receptor gamma Mus musculus 107-117 21219874-7 2011 These increases were abolished by cotreatment with GW9662, a PPARgamma antagonist. 2-chloro-5-nitrobenzanilide 51-57 peroxisome proliferator activated receptor gamma Mus musculus 61-70 21156825-9 2011 A PPARgamma antagonist, GW9662, abolished telmisartan-induced inhibition. 2-chloro-5-nitrobenzanilide 24-30 peroxisome proliferator activated receptor gamma Mus musculus 2-11 21364286-7 2011 Since GH signaling represses PPARgamma expression and Cd36 is a known transcriptional target of PPARgamma, we treated JAK2L mice with the PPARgamma-specific antagonist GW9662. 2-chloro-5-nitrobenzanilide 168-174 peroxisome proliferator activated receptor gamma Mus musculus 96-105 21364286-7 2011 Since GH signaling represses PPARgamma expression and Cd36 is a known transcriptional target of PPARgamma, we treated JAK2L mice with the PPARgamma-specific antagonist GW9662. 2-chloro-5-nitrobenzanilide 168-174 peroxisome proliferator activated receptor gamma Mus musculus 96-105 21493225-15 2011 The effects of PPAR-gamma agonist on Foxp3 mRNA expression and Tregs induction were abrogated by administration of GW9662. 2-chloro-5-nitrobenzanilide 115-121 peroxisome proliferator activated receptor gamma Mus musculus 15-25 21356367-7 2011 The use of the CB2 antagonist AM630 or the PPARgamma antagonist GW9662 significantly reversed the protective effect of BCP. 2-chloro-5-nitrobenzanilide 64-70 peroxisome proliferator activated receptor gamma Mus musculus 43-52 20665707-10 2011 Inhibition of PPARgamma by co-administration of GW9662, however, abolished the salutary effects of 17beta-estradiol on plasma cytokine and Kupffer cells. 2-chloro-5-nitrobenzanilide 48-54 peroxisome proliferator activated receptor gamma Mus musculus 14-23 19219624-6 2009 Pre-treatment of cells with the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) antagonists GW9662 (0.1-1 microM) or biphenol A Diglycidyl Ether (100-200 microM) resulted in reduction of the induction of COX-2 by diclofenac, but not by LPS. 2-chloro-5-nitrobenzanilide 106-112 peroxisome proliferator activated receptor gamma Mus musculus 32-80 19954946-9 2010 Most interestingly, we found that treatment of luteolin markedly enhanced peroxisome proliferator-activated receptor gamma (PPARgamma) transcriptional activity in 3T3-L1 adipocytes, and luteolin-increased expression of adiponectin and leptin was blocked by GW9662, a PPARgamma antagonist. 2-chloro-5-nitrobenzanilide 257-263 peroxisome proliferator activated receptor gamma Mus musculus 74-122 19932165-6 2010 This induction of PPARgamma expression was completely abolished by the PPARgamma antagonist GW9662. 2-chloro-5-nitrobenzanilide 92-98 peroxisome proliferator activated receptor gamma Mus musculus 18-27 19932165-6 2010 This induction of PPARgamma expression was completely abolished by the PPARgamma antagonist GW9662. 2-chloro-5-nitrobenzanilide 92-98 peroxisome proliferator activated receptor gamma Mus musculus 71-80 19846417-11 2009 Treatment with the PPARgamma inhibitor GW9662 partially reversed TLR4 expression in immature BMDC. 2-chloro-5-nitrobenzanilide 39-45 peroxisome proliferator activated receptor gamma Mus musculus 19-28 19635982-12 2009 Cotreatment with GW9662, a PPAR-gamma antagonist, attenuated this telmisartan-mediated improvement of cognition. 2-chloro-5-nitrobenzanilide 17-23 peroxisome proliferator activated receptor gamma Mus musculus 27-37 19737384-5 2009 Finally, an important collateral vessel growth is obtained with combined treatment with pioglitazone and selective PPARgamma inhibitor GW9662. 2-chloro-5-nitrobenzanilide 135-141 peroxisome proliferator activated receptor gamma Mus musculus 115-124 19460355-6 2009 The beneficial effects of nifedipine on AGE-exposed mesangial cells were blocked by the simultaneous treatment of GW9662, an inhibitor of peroxisome proliferator-activated receptor-gamma (PPAR-gamma). 2-chloro-5-nitrobenzanilide 114-120 peroxisome proliferator activated receptor gamma Mus musculus 138-186 19460355-6 2009 The beneficial effects of nifedipine on AGE-exposed mesangial cells were blocked by the simultaneous treatment of GW9662, an inhibitor of peroxisome proliferator-activated receptor-gamma (PPAR-gamma). 2-chloro-5-nitrobenzanilide 114-120 peroxisome proliferator activated receptor gamma Mus musculus 188-198 19422805-3 2009 In this study, an antagonist of PPARgamma, GW9662, was injected into the fourth ventricle of APP/PS1 transgenic mice to inhibit PPARgamma activity in cerebellum. 2-chloro-5-nitrobenzanilide 43-49 peroxisome proliferator activated receptor gamma Mus musculus 32-41 19422805-3 2009 In this study, an antagonist of PPARgamma, GW9662, was injected into the fourth ventricle of APP/PS1 transgenic mice to inhibit PPARgamma activity in cerebellum. 2-chloro-5-nitrobenzanilide 43-49 peroxisome proliferator activated receptor gamma Mus musculus 128-137 19229877-5 2009 PPAR-gamma overexpression alone was effective in maintaining MMP and preventing apoptosis and its protective effect was also abrogated by PPAR-gamma siRNA or GW9662. 2-chloro-5-nitrobenzanilide 158-164 peroxisome proliferator activated receptor gamma Mus musculus 0-10 19348833-6 2009 The PPAR gamma agonists 15-deoxy-Delta(12,14)-prostaglandin J(2) and ciglitazone decreased the basal and FFA-enhanced YP uptake, while the antagonist GW9662 increased YP uptake, this effect being blocked by the agonists and also by oxATP. 2-chloro-5-nitrobenzanilide 150-156 peroxisome proliferator activated receptor gamma Mus musculus 4-14 20650758-9 2010 When PPAR gamma was specifically inhibited by GW9662 and PPARgamma-SiRNA, the protective effects of rosiglitazone and pioglitazone were almost undetectable, and the apoptotic rate increased and insulin secretion decreased to the level of the cytokine-treated cells. 2-chloro-5-nitrobenzanilide 46-52 peroxisome proliferator activated receptor gamma Mus musculus 5-15 19997048-7 2010 Peroxisome proliferator-activated receptor gamma antagonist, GW9662, prevented all these 15dPGJ2 actions. 2-chloro-5-nitrobenzanilide 61-67 peroxisome proliferator activated receptor gamma Mus musculus 0-48 19953004-7 2010 Moreover, GW9662 (a peroxisome proliferator-activated receptor gamma antagonist) prevented the inhibitory effect of TZDs on NFATc1 expression and osteoclast differentiation. 2-chloro-5-nitrobenzanilide 10-16 peroxisome proliferator activated receptor gamma Mus musculus 20-68 19833717-7 2009 The induction of adiponectin by tocopherols seems to be PPARgamma dependent, because it was blocked by the specific antagonist GW9662. 2-chloro-5-nitrobenzanilide 127-133 peroxisome proliferator activated receptor gamma Mus musculus 56-65 20019843-5 2009 These effects were not elicited through PPARgamma-dependent pathways because an irreversible PPARgamma antagonist GW9662 did not inhibit these effects. 2-chloro-5-nitrobenzanilide 114-120 peroxisome proliferator activated receptor gamma Mus musculus 93-102 19219624-6 2009 Pre-treatment of cells with the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) antagonists GW9662 (0.1-1 microM) or biphenol A Diglycidyl Ether (100-200 microM) resulted in reduction of the induction of COX-2 by diclofenac, but not by LPS. 2-chloro-5-nitrobenzanilide 106-112 peroxisome proliferator activated receptor gamma Mus musculus 82-92 19219624-7 2009 Induction of COX-2 by the PPAR-gamma agonist 15deoxyDelta(12,14)prostaglandin J(2) was also reduced when the cells were pre-treated with the PPAR-gamma antagonists BADGE or GW9662. 2-chloro-5-nitrobenzanilide 173-179 peroxisome proliferator activated receptor gamma Mus musculus 26-36 19219624-7 2009 Induction of COX-2 by the PPAR-gamma agonist 15deoxyDelta(12,14)prostaglandin J(2) was also reduced when the cells were pre-treated with the PPAR-gamma antagonists BADGE or GW9662. 2-chloro-5-nitrobenzanilide 173-179 peroxisome proliferator activated receptor gamma Mus musculus 141-151 18566389-7 2008 Overexpression of PPARgamma prevented LPS-stimulated M-CSF production in RAW 264.7 cells, an effect that was abrogated by a specific PPARgamma antagonist, GW9662. 2-chloro-5-nitrobenzanilide 155-161 peroxisome proliferator activated receptor gamma Mus musculus 18-27 18948087-10 2008 Treatment with GW9662 (a specific PPARgamma antagonist) prevented all the above PPARgamma-mediated actions. 2-chloro-5-nitrobenzanilide 15-21 peroxisome proliferator activated receptor gamma Mus musculus 34-43 18948087-10 2008 Treatment with GW9662 (a specific PPARgamma antagonist) prevented all the above PPARgamma-mediated actions. 2-chloro-5-nitrobenzanilide 15-21 peroxisome proliferator activated receptor gamma Mus musculus 80-89 18535203-9 2008 Finally, treatment with the PPAR-gamma antagonist GW9662 significantly reversed the inhibition of PMN chemotaxis and increased peritoneal PMN recruitment in murine sepsis. 2-chloro-5-nitrobenzanilide 50-56 peroxisome proliferator activated receptor gamma Mus musculus 28-38 18790758-4 2008 MCC-555 increased MUC2 expression in colorectal and lung cancer cells, and treatment with the PPARgamma antagonist GW9662 revealed that MUC2 induction by MCC-555 was mediated in a PPARgamma-dependent manner. 2-chloro-5-nitrobenzanilide 115-121 peroxisome proliferator activated receptor gamma Mus musculus 94-103 18790758-4 2008 MCC-555 increased MUC2 expression in colorectal and lung cancer cells, and treatment with the PPARgamma antagonist GW9662 revealed that MUC2 induction by MCC-555 was mediated in a PPARgamma-dependent manner. 2-chloro-5-nitrobenzanilide 115-121 peroxisome proliferator activated receptor gamma Mus musculus 180-189 18579278-13 2008 GW-9662 (10 microg/site, i.c.v, a PPARgamma antagonist) administered 15 min before NP03115 (5 mg/kg, i.p.) 2-chloro-5-nitrobenzanilide 0-7 peroxisome proliferator activated receptor gamma Mus musculus 34-43 19048458-6 2009 Furthermore, 3T3L1 cells were incubated in medium containing GW9662 (PPARgamma antagonist) together with benzbromarone or pioglitazone, after which real-time PCR assays were performed for messenger RNA of adiponectin. 2-chloro-5-nitrobenzanilide 61-67 peroxisome proliferator activated receptor gamma Mus musculus 69-78 18715543-5 2008 Interestingly, co-treatment with GW9662, a PPAR-gamma antagonist, partially inhibited this improvement of cognitive decline. 2-chloro-5-nitrobenzanilide 33-39 peroxisome proliferator activated receptor gamma Mus musculus 43-53 18567757-4 2008 Subgroups of mice were coadministered 20 micromol/L of the selective PPARgamma antagonist GW9662 during each OVA challenge. 2-chloro-5-nitrobenzanilide 90-96 peroxisome proliferator activated receptor gamma Mus musculus 69-78 18356564-13 2008 Moreover, inhibition of peroxysome proliferator-activated receptor (PPAR)-gamma, an antiinflammatory nuclear regulator, by GW9662 abolished the protective effects of CO. 2-chloro-5-nitrobenzanilide 123-129 peroxisome proliferator activated receptor gamma Mus musculus 24-79 18566389-7 2008 Overexpression of PPARgamma prevented LPS-stimulated M-CSF production in RAW 264.7 cells, an effect that was abrogated by a specific PPARgamma antagonist, GW9662. 2-chloro-5-nitrobenzanilide 155-161 peroxisome proliferator activated receptor gamma Mus musculus 133-142